Human genome meeting 2016

Table of contents O1 The metabolomics approach to autism: identification of biomarkers for early detection of autism spectrum disorder A. K. Srivastava, Y. Wang, R. Huang, C. Skinner, T. Thompson, L. Pollard, T. Wood, F. Luo, R. Stevenson O2 Phenome-wide association study for smoking- and drinking-associated genes in 26,394 American women with African, Asian, European, and Hispanic descents R. Polimanti, J. Gelernter O3 Effects of prenatal environment, genotype and DNA methylation on birth weight and subsequent postnatal outcomes: findings from GUSTO, an Asian birth cohort X. Lin, I. Y. Lim, Y. Wu, A. L. Teh, L. Chen, I. M. Aris, S. E. Soh, M. T. Tint, J. L. MacIsaac, F. Yap, K. Kwek, S. M. Saw, M. S. Kobor, M. J. Meaney, K. M. Godfrey, Y. S. Chong, J. D. Holbrook, Y. S. Lee, P. D. Gluckman, N. Karnani, GUSTO study group O4 High-throughput identification of specific qt interval modulating enhancers at the SCN5A locus A. Kapoor, D. Lee, A. Chakravarti O5 Identification of extracellular matrix components inducing cancer cell migration in the supernatant of cultivated mesenchymal stem cells C. Maercker, F. Graf, M. Boutros O6 Single cell allele specific expression (ASE) IN T21 and common trisomies: a novel approach to understand DOWN syndrome and other aneuploidies G. Stamoulis, F. Santoni, P. Makrythanasis, A. Letourneau, M. Guipponi, N. Panousis, M. Garieri, P. Ribaux, E. Falconnet, C. Borel, S. E. Antonarakis O7 Role of microRNA in LCL to IPSC reprogramming S. Kumar, J. Curran, J. Blangero O8 Multiple enhancer variants disrupt gene regulatory network in Hirschsprung disease S. Chatterjee, A. Kapoor, J. Akiyama, D. Auer, C. Berrios, L. Pennacchio, A. Chakravarti O9 Metabolomic profiling for the diagnosis of neurometabolic disorders T. R. Donti, G. Cappuccio, M. Miller, P. Atwal, A. Kennedy, A. Cardon, C. Bacino, L. Emrick, J. Hertecant, F. Baumer, B. Porter, M. Bainbridge, P. Bonnen, B. Graham, R. Sutton, Q. Sun, S. Elsea O10 A novel causal methylation network approach to Alzheimer’s disease Z. Hu, P. Wang, Y. Zhu, J. Zhao, M. Xiong, David A Bennett O11 A microRNA signature identifies subtypes of triple-negative breast cancer and reveals MIR-342-3P as regulator of a lactate metabolic pathway A. Hidalgo-Miranda, S. Romero-Cordoba, S. Rodriguez-Cuevas, R. Rebollar-Vega, E. Tagliabue, M. Iorio, E. D’Ippolito, S. Baroni O12 Transcriptome analysis identifies genes, enhancer RNAs and repetitive elements that are recurrently deregulated across multiple cancer types B. Kaczkowski, Y. Tanaka, H. Kawaji, A. Sandelin, R. Andersson, M. Itoh, T. Lassmann, the FANTOM5 consortium, Y. Hayashizaki, P. Carninci, A. R. R. Forrest O13 Elevated mutation and widespread loss of constraint at regulatory and architectural binding sites across 11 tumour types C. A. Semple O14 Exome sequencing provides evidence of pathogenicity for genes implicated in colorectal cancer E. A. Rosenthal, B. Shirts, L. Amendola, C. Gallego, M. Horike-Pyne, A. Burt, P. Robertson, P. Beyers, C. Nefcy, D. Veenstra, F. Hisama, R. Bennett, M. Dorschner, D. Nickerson, J. Smith, K. Patterson, D. Crosslin, R. Nassir, N. Zubair, T. Harrison, U. Peters, G. Jarvik, NHLBI GO Exome Sequencing Project O15 The tandem duplicator phenotype as a distinct genomic configuration in cancer F. Menghi, K. Inaki, X. Woo, P. Kumar, K. Grzeda, A. Malhotra, H. Kim, D. Ucar, P. Shreckengast, K. Karuturi, J. Keck, J. Chuang, E. T. Liu O16 Modeling genetic interactions associated with molecular subtypes of breast cancer B. Ji, A. Tyler, G. Ananda, G. Carter O17 Recurrent somatic mutation in the MYC associated factor X in brain tumors H. Nikbakht, M. Montagne, M. Zeinieh, A. Harutyunyan, M. Mcconechy, N. Jabado, P. Lavigne, J. Majewski O18 Predictive biomarkers to metastatic pancreatic cancer treatment J. B. Goldstein, M. Overman, G. Varadhachary, R. Shroff, R. Wolff, M. Javle, A. Futreal, D. Fogelman O19 DDIT4 gene expression as a prognostic marker in several malignant tumors L. Bravo, W. Fajardo, H. Gomez, C. Castaneda, C. Rolfo, J. A. Pinto O20 Spatial organization of the genome and genomic alterations in human cancers K. C. Akdemir, L. Chin, A. Futreal, ICGC PCAWG Structural Alterations Group O21 Landscape of targeted therapies in solid tumors S. Patterson, C. Statz, S. Mockus O22 Genomic analysis reveals novel drivers and progression pathways in skin basal cell carcinoma S. N. Nikolaev, X. I. Bonilla, L. Parmentier, B. King, F. Bezrukov, G. Kaya, V. Zoete, V. Seplyarskiy, H. Sharpe, T. McKee, A. Letourneau, P. Ribaux, K. Popadin, N. Basset-Seguin, R. Ben Chaabene, F. Santoni, M. Andrianova, M. Guipponi, M. Garieri, C. Verdan, K. Grosdemange, O. Sumara, M. Eilers, I. Aifantis, O. Michielin, F. de Sauvage, S. Antonarakis O23 Identification of differential biomarkers of hepatocellular carcinoma and cholangiocarcinoma via transcriptome microarray meta-analysis S. Likhitrattanapisal O24 Clinical validity and actionability of multigene tests for hereditary cancers in a large multi-center study S. Lincoln, A. Kurian, A. Desmond, S. Yang, Y. Kobayashi, J. Ford, L. Ellisen O25 Correlation with tumor ploidy status is essential for correct determination of genome-wide copy number changes by SNP array T. L. Peters, K. R. Alvarez, E. F. Hollingsworth, D. H. Lopez-Terrada O26 Nanochannel based next-generation mapping for interrogation of clinically relevant structural variation A. Hastie, Z. Dzakula, A. W. Pang, E. T. Lam, T. Anantharaman, M. Saghbini, H. Cao, BioNano Genomics O27 Mutation spectrum in a pulmonary arterial hypertension (PAH) cohort and identification of associated truncating mutations in TBX4 C. Gonzaga-Jauregui, L. Ma, A. King, E. Berman Rosenzweig, U. Krishnan, J. G. Reid, J. D. Overton, F. Dewey, W. K. Chung O28 NORTH CAROLINA macular dystrophy (MCDR1): mutations found affecting PRDM13 K. Small, A. DeLuca, F. Cremers, R. A. Lewis, V. Puech, B. Bakall, R. Silva-Garcia, K. Rohrschneider, M. Leys, F. S. Shaya, E. Stone O29 PhenoDB and genematcher, solving unsolved whole exome sequencing data N. L. Sobreira, F. Schiettecatte, H. Ling, E. Pugh, D. Witmer, K. Hetrick, P. Zhang, K. Doheny, D. Valle, A. Hamosh O30 Baylor-Johns Hopkins Center for Mendelian genomics: a four year review S. N. Jhangiani, Z. Coban Akdemir, M. N. Bainbridge, W. Charng, W. Wiszniewski, T. Gambin, E. Karaca, Y. Bayram, M. K. Eldomery, J. Posey, H. Doddapaneni, J. Hu, V. R. Sutton, D. M. Muzny, E. A. Boerwinkle, D. Valle, J. R. Lupski, R. A. Gibbs O31 Using read overlap assembly to accurately identify structural genetic differences in an ashkenazi jewish trio S. Shekar, W. Salerno, A. English, A. Mangubat, J. Bruestle O32 Legal interoperability: a sine qua non for international data sharing A. Thorogood, B. M. Knoppers, Global Alliance for Genomics and Health - Regulatory and Ethics Working Group O33 High throughput screening platform of competent sineups: that can enhance translation activities of therapeutic target H. Takahashi, K. R. Nitta, A. Kozhuharova, A. M. Suzuki, H. Sharma, D. Cotella, C. Santoro, S. Zucchelli, S. Gustincich, P. Carninci O34 The undiagnosed diseases network international (UDNI): clinical and laboratory research to meet patient needs J. J. Mulvihill, G. Baynam, W. Gahl, S. C. Groft, K. Kosaki, P. Lasko, B. Melegh, D. Taruscio O36 Performance of computational algorithms in pathogenicity predictions for activating variants in oncogenes versus loss of function mutations in tumor suppressor genes R. Ghosh, S. Plon O37 Identification and electronic health record incorporation of clinically actionable pharmacogenomic variants using prospective targeted sequencing S. Scherer, X. Qin, R. Sanghvi, K. Walker, T. Chiang, D. Muzny, L. Wang, J. Black, E. Boerwinkle, R. Weinshilboum, R. Gibbs O38 Melanoma reprogramming state correlates with response to CTLA-4 blockade in metastatic melanoma T. Karpinets, T. Calderone, K. Wani, X. Yu, C. Creasy, C. Haymaker, M. Forget, V. Nanda, J. Roszik, J. Wargo, L. Haydu, X. Song, A. Lazar, J. Gershenwald, M. Davies, C. Bernatchez, J. Zhang, A. Futreal, S. Woodman O39 Data-driven refinement of complex disease classification from integration of heterogeneous functional genomics data in GeneWeaver E. J. Chesler, T. Reynolds, J. A. Bubier, C. Phillips, M. A. Langston, E. J. Baker O40 A general statistic framework for genome-based disease risk prediction M. Xiong, L. Ma, N. Lin, C. Amos O41 Integrative large-scale causal network analysis of imaging and genomic data and its application in schizophrenia studies N. Lin, P. Wang, Y. Zhu, J. Zhao, V. Calhoun, M. Xiong O42 Big data and NGS data analysis: the cloud to the rescue O. Dobretsberger, M. Egger, F. Leimgruber O43 Cpipe: a convergent clinical exome pipeline specialised for targeted sequencing S. Sadedin, A. Oshlack, Melbourne Genomics Health Alliance O44 A Bayesian classification of biomedical images using feature extraction from deep neural networks implemented on lung cancer data V. A. A. Antonio, N. Ono, Clark Kendrick C. Go O45 MAV-SEQ: an interactive platform for the Management, Analysis, and Visualization of sequence data Z. Ahmed, M. Bolisetty, S. Zeeshan, E. Anguiano, D. Ucar O47 Allele specific enhancer in EPAS1 intronic regions may contribute to high altitude adaptation of Tibetans C. Zeng, J. Shao O48 Nanochannel based next-generation mapping for structural variation detection and comparison in trios and populations H. Cao, A. Hastie, A. W. Pang, E. T. Lam, T. Liang, K. Pham, M. Saghbini, Z. Dzakula O49 Archaic introgression in indigenous populations of Malaysia revealed by whole genome sequencing Y. Chee-Wei, L. Dongsheng, W. Lai-Ping, D. Lian, R. O. Twee Hee, Y. Yunus, F. Aghakhanian, S. S. Mokhtar, C. V. Lok-Yung, J. Bhak, M. Phipps, X. Shuhua, T. Yik-Ying, V. Kumar, H. Boon-Peng O50 Breast and ovarian cancer prevention: is it time for population-based mutation screening of high risk genes? I. Campbell, M.-A. Young, P. James, Lifepool O53 Comprehensive coverage from low DNA input using novel NGS library preparation methods for WGS and WGBS C. Schumacher, S. Sandhu, T. Harkins, V. Makarov O54 Methods for large scale construction of robust PCR-free libraries for sequencing on Illumina HiSeqX platform H. DoddapaneniR. Glenn, Z. Momin, B. Dilrukshi, H. Chao, Q. Meng, B. Gudenkauf, R. Kshitij, J. Jayaseelan, C. Nessner, S. Lee, K. Blankenberg, L. Lewis, J. Hu, Y. Han, H. Dinh, S. Jireh, K. Walker, E. Boerwinkle, D. Muzny, R. Gibbs O55 Rapid capture methods for clinical sequencing J. Hu, K. Walker, C. Buhay, X. Liu, Q. Wang, R. Sanghvi, H. Doddapaneni, Y. Ding, N. Veeraraghavan, Y. Yang, E. Boerwinkle, A. L. Beaudet, C. M. Eng, D. M. Muzny, R. A. Gibbs O56 A diploid personal human genome model for better genomes from diverse sequence data K. C. C. Worley, Y. Liu, D. S. T. Hughes, S. C. Murali, R. A. Harris, A. C. English, X. Qin, O. A. Hampton, P. Larsen, C. Beck, Y. Han, M. Wang, H. Doddapaneni, C. L. Kovar, W. J. Salerno, A. Yoder, S. Richards, J. Rogers, J. R. Lupski, D. M. Muzny, R. A. Gibbs O57 Development of PacBio long range capture for detection of pathogenic structural variants Q. Meng, M. Bainbridge, M. Wang, H. Doddapaneni, Y. Han, D. Muzny, R. Gibbs O58 Rhesus macaques exhibit more non-synonymous variation but greater impact of purifying selection than humans R. A. Harris, M. Raveenedran, C. Xue, M. Dahdouli, L. Cox, G. Fan, B. Ferguson, J. Hovarth, Z. Johnson, S. Kanthaswamy, M. Kubisch, M. Platt, D. Smith, E. Vallender, R. Wiseman, X. Liu, J. Below, D. Muzny, R. Gibbs, F. Yu, J. Rogers O59 Assessing RNA structure disruption induced by single-nucleotide variation J. Lin, Y. Zhang, Z. Ouyang P1 A meta-analysis of genome-wide association studies of mitochondrial dna copy number A. Moore, Z. Wang, J. Hofmann, M. Purdue, R. Stolzenberg-Solomon, S. Weinstein, D. Albanes, C.-S. Liu, W.-L. Cheng, T.-T. Lin, Q. Lan, N. Rothman, S. Berndt P2 Missense polymorphic genetic combinations underlying down syndrome susceptibility E. S. Chen P4 The evaluation of alteration of ELAM-1 expression in the endometriosis patients H. Bahrami, A. Khoshzaban, S. Heidari Keshal P5 Obesity and the incidence of apolipoprotein E polymorphisms in an assorted population from Saudi Arabia population K. K. R. Alharbi P6 Genome-associated personalized antithrombotical therapy for patients with high risk of thrombosis and bleeding M. Zhalbinova, A. Akilzhanova, S. Rakhimova, M. Bekbosynova, S. Myrzakhmetova P7 Frequency of Xmn1 polymorphism among sickle cell carrier cases in UAE population M. Matar P8 Differentiating inflammatory bowel diseases by using genomic data: dimension of the problem and network organization N. Mili, R. Molinari, Y. Ma, S. Guerrier P9 Vulnerability of genetic variants to the risk of autism among Saudi children N. Elhawary, M. Tayeb, N. Bogari, N. Qotb P10 Chromatin profiles from ex vivo purified dopaminergic neurons establish a promising model to support studies of neurological function and dysfunction S. A. McClymont, P. W. Hook, L. A. Goff, A. McCallion P11 Utilization of a sensitized chemical mutagenesis screen to identify genetic modifiers of retinal dysplasia in homozygous Nr2e3rd7 mice Y. Kong, J. R. Charette, W. L. Hicks, J. K. Naggert, L. Zhao, P. M. Nishina P12 Ion torrent next generation sequencing of recessive polycystic kidney disease in Saudi patients B. M. Edrees, M. Athar, F. A. Al-Allaf, M. M. Taher, W. Khan, A. Bouazzaoui, N. A. Harbi, R. Safar, H. Al-Edressi, A. Anazi, N. Altayeb, M. A. Ahmed, K. Alansary, Z. Abduljaleel P13 Digital expression profiling of Purkinje neurons and dendrites in different subcellular compartments A. Kratz, P. Beguin, S. Poulain, M. Kaneko, C. Takahiko, A. Matsunaga, S. Kato, A. M. Suzuki, N. Bertin, T. Lassmann, R. Vigot, P. Carninci, C. Plessy, T. Launey P14 The evolution of imperfection and imperfection of evolution: the functional and functionless fractions of the human genome D. Graur P16 Species-independent identification of known and novel recurrent genomic entities in multiple cancer patients J. Friis-Nielsen, J. M. Izarzugaza, S. Brunak P18 Discovery of active gene modules which are densely conserved across multiple cancer types reveal their prognostic power and mutually exclusive mutation patterns B. S. Soibam P19 Whole exome sequencing of dysplastic leukoplakia tissue indicates sequential accumulation of somatic mutations from oral precancer to cancer D. Das, N. Biswas, S. Das, S. Sarkar, A. Maitra, C. Panda, P. Majumder P21 Epigenetic mechanisms of carcinogensis by hereditary breast cancer genes J. J. Gruber, N. Jaeger, M. Snyder P22 RNA direct: a novel RNA enrichment strategy applied to transcripts associated with solid tumors K. Patel, S. Bowman, T. Davis, D. Kraushaar, A. Emerman, S. Russello, N. Henig, C. Hendrickson P23 RNA sequencing identifies gene mutations for neuroblastoma K. Zhang P24 Participation of SFRP1 in the modulation of TMPRSS2-ERG fusion gene in prostate cancer cell lines M. Rodriguez-Dorantes, C. D. Cruz-Hernandez, C. D. P. Garcia-Tobilla, S. Solorzano-Rosales P25 Targeted Methylation Sequencing of Prostate Cancer N. Jäger, J. Chen, R. Haile, M. Hitchins, J. D. Brooks, M. Snyder P26 Mutant TPMT alleles in children with acute lymphoblastic leukemia from México City and Yucatán, Mexico S. Jiménez-Morales, M. Ramírez, J. Nuñez, V. Bekker, Y. Leal, E. Jiménez, A. Medina, A. Hidalgo, J. Mejía P28 Genetic modifiers of Alström syndrome J. Naggert, G. B. Collin, K. DeMauro, R. Hanusek, P. M. Nishina P31 Association of genomic variants with the occurrence of angiotensin-converting-enzyme inhibitor (ACEI)-induced coughing among Filipinos E. M. Cutiongco De La Paz, R. Sy, J. Nevado, P. Reganit, L. Santos, J. D. Magno, F. E. Punzalan , D. Ona , E. Llanes, R. L. Santos-Cortes , R. Tiongco, J. Aherrera, L. Abrahan, P. Pagauitan-Alan; Philippine Cardiogenomics Study Group P32 The use of “humanized” mouse models to validate disease association of a de novo GARS variant and to test a novel gene therapy strategy for Charcot-Marie-Tooth disease type 2D K. H. Morelli, J. S. Domire, N. Pyne, S. Harper, R. Burgess P34 Molecular regulation of chondrogenic human induced pluripotent stem cells M. A. Gari, A. Dallol, H. Alsehli, A. Gari, M. Gari, A. Abuzenadah P35 Molecular profiling of hematologic malignancies: implementation of a variant assessment algorithm for next generation sequencing data analysis and clinical reporting M. Thomas, M. Sukhai, S. Garg, M. Misyura, T. Zhang, A. Schuh, T. Stockley, S. Kamel-Reid P36 Accessing genomic evidence for clinical variants at NCBI S. Sherry, C. Xiao, D. Slotta, K. Rodarmer, M. Feolo, M. Kimelman, G. Godynskiy, C. O’Sullivan, E. Yaschenko P37 NGS-SWIFT: a cloud-based variant analysis framework using control-accessed sequencing data from DBGAP/SRA C. Xiao, E. Yaschenko, S. Sherry P38 Computational assessment of drug induced hepatotoxicity through gene expression profiling C. Rangel-Escareño, H. Rueda-Zarate P40 Flowr: robust and efficient pipelines using a simple language-agnostic approach;ultraseq; fast modular pipeline for somatic variation calling using flowr S. Seth, S. Amin, X. Song, X. Mao, H. Sun, R. G. Verhaak, A. Futreal, J. Zhang P41 Applying “Big data” technologies to the rapid analysis of heterogenous large cohort data S. J. Whiite, T. Chiang, A. English, J. Farek, Z. Kahn, W. Salerno, N. Veeraraghavan, E. Boerwinkle, R. Gibbs P42 FANTOM5 web resource for the large-scale genome-wide transcription start site activity profiles of wide-range of mammalian cells T. Kasukawa, M. Lizio, J. Harshbarger, S. Hisashi, J. Severin, A. Imad, S. Sahin, T. C. Freeman, K. Baillie, A. Sandelin, P. Carninci, A. R. R. Forrest, H. Kawaji, The FANTOM Consortium P43 Rapid and scalable typing of structural variants for disease cohorts W. Salerno, A. English, S. N. Shekar, A. Mangubat, J. Bruestle, E. Boerwinkle, R. A. Gibbs P44 Polymorphism of glutathione S-transferases and sulphotransferases genes in an Arab population A. H. Salem, M. Ali, A. Ibrahim, M. Ibrahim P46 Genetic divergence of CYP3A5*3 pharmacogenomic marker for native and admixed Mexican populations J. C. Fernandez-Lopez, V. Bonifaz-Peña, C. Rangel-Escareño, A. Hidalgo-Miranda, A. V. Contreras P47 Whole exome sequence meta-analysis of 13 white blood cell, red blood cell, and platelet traits L. Polfus, CHARGE and NHLBI Exome Sequence Project Working Groups P48 Association of adipoq gene with type 2 diabetes and related phenotypes in african american men and women: The jackson heart study S. Davis, R. Xu, S. Gebeab, P Riestra, A Gaye, R. Khan, J. Wilson, A. Bidulescu P49 Common variants in casr gene are associated with serum calcium levels in koreans S. H. Jung, N. Vinayagamoorthy, S. H. Yim, Y. J. Chung P50 Inference of multiple-wave population admixture by modeling decay of linkage disequilibrium with multiple exponential functions Y. Zhou, S. Xu P51 A Bayesian framework for generalized linear mixed models in genome-wide association studies X. Wang, V. Philip, G. Carter P52 Targeted sequencing approach for the identification of the genetic causes of hereditary hearing impairment A. A. Abuzenadah, M. Gari, R. Turki, A. Dallol P53 Identification of enhancer sequences by ATAC-seq open chromatin profiling A. Uyar, A. Kaygun, S. Zaman, E. Marquez, J. George, D. Ucar P54 Direct enrichment for the rapid preparation of targeted NGS libraries C. L. Hendrickson, A. Emerman, D. Kraushaar, S. Bowman, N. Henig, T. Davis, S. Russello, K. Patel P56 Performance of the Agilent D5000 and High Sensitivity D5000 ScreenTape assays for the Agilent 4200 Tapestation System R. Nitsche, L. Prieto-Lafuente P57 ClinVar: a multi-source archive for variant interpretation M. Landrum, J. Lee, W. Rubinstein, D. Maglott P59 Association of functional variants and protein physical interactions of human MUTY homolog linked with familial adenomatous polyposis and colorectal cancer syndrome Z. Abduljaleel, W. Khan, F. A. Al-Allaf, M. Athar , M. M. Taher, N. Shahzad P60 Modification of the microbiom constitution in the gut using chicken IgY antibodies resulted in a reduction of acute graft-versus-host disease after experimental bone marrow transplantation A. Bouazzaoui, E. Huber, A. Dan, F. A. Al-Allaf, W. Herr, G. Sprotte, J. Köstler, A. Hiergeist, A. Gessner, R. Andreesen, E. Holler P61 Compound heterozygous mutation in the LDLR gene in Saudi patients suffering severe hypercholesterolemia F. Al-Allaf, A. Alashwal, Z. Abduljaleel, M. Taher, A. Bouazzaoui, H. Abalkhail, A. Al-Allaf, R. Bamardadh, M. Athar


Objectives
From the first description by Leo Kanner [1], autism has been an enigmatic neurobehavioral phenomenon. The new genetic/genomic technologies of the past decade have not been as productive as originally anticipated in unveiling the mysteries of autism. The specific etiology of the majority of cases of autism spectrum disorder (ASD) is unknown, although numerous genetic/genomic variants and alterations of diverse cellular functions have been reported. Prompted by this failure, we have investigated whether the metabolomics approach might yield results which could simultaneously lead to a blood-based screening/diagnostic test and to treatment options. Methods Plasma samples from a clinically well-defined cohort of 100 male individuals, ages 2-16+ years, with ASD and 32 age-matched typically developing (TD) controls were subjected to global metabolomic analysis.

Results
We have identified more than 25 plasma metabolites among the approximately 650 metabolites analyzed, representing over 70 biochemical pathways, that can discriminate children with ASD as young as 2 years from children that are developing typically. The discriminating power was greatest in the 2-10 year age group and weaker in older age groups. The initial findings were validated in a second cohort of 83 children, males and females, ages 2-10 years, with ASD and 76 age and gender-matched TD children. The discriminant metabolites were associated with several key biochemical pathways suggestive of potential contributions of increased oxidative stress, mitochondrial dysfunction, inflammation and immune dysregulation in ASD. Further, targeted quantitative analysis of a subset of discriminating metabolites using tandem mass spectrometry provided a reliable laboratory method to detect children with ASD.
Conclusion Metabolic profiling appears to be a robust technique to identify children with ASD ages 2-10 years and provides insights into the altered metabolic pathways in ASD, which could lead to treatment strategies.

Objectives
To uncover novel traits associated with nicotine and alcohol use genetics, we performed a phenome-wide association study in a large multi-ethnic cohort. Methods We investigated 7,688 African-Americans (AFR), 1,133 Asian-Americans (ASN), 14,081 European-Americans (EUR), and 3,492 Hispanic-Americans (HISP) from the Women's Health Initiative, analyzing risk alleles located in the CHRNA5-CHRNA3 locus (rs8034191, rs1051730, rs12914385, rs2036527, and rs16969968) for nicotine-related traits and ADH1B (rs1229984 and rs2066702) and ALDH2 (rs671) for alcohol-related traits with respect to anthropometric characteristics, dietary habits, social status, psychological circumstances, reproductive history, health conditions, and nicotine-and alcohol-related traits.

Conclusion
We provided novel genetic data regarding the consequences of smoking and drinking behaviors and confirmed ethnic differences in their genetic predisposition.

Objectives
Prenatal environment and genetic polymorphism can have a lasting impact on offspring's metabolic function by perturbing its epigenome. Birth weight is often used as a surrogate for the overall quality of the intrauterine environment. We present the first neonate epigenome-wide association study in an Asian mother-offspring cohort, that interrogates the effects of prenatal environment variables, umbilical cord DNA methylation and SNPs, on birth weight.

Methods
In GUSTO, a prospective mother-offspring cohort study (N=987), we examined the associations between DNA methylation, SNPs, birth weight and 11 prenatal environment variables. First, we investigated the association between perinatal methylome and birth weight to identify sites of variability in methylation. Second, we interrogated the contribution of genetic and prenatal environmental factors on this variability in the epigenome. Finally, we examined whether these methylation marks at birth were associated with offspring size and adiposity in early childhood.

Results
Methylation levels at 50 CpGs were significantly associated with birth weight, and a subset of these CpGs was located in genes and miRNA known to be involved in metabolic pathways/disorders. We further examined the influence of environmental and genetic factors on methylation at these 50 CpG sites. Sixteen CpGs were associated with both, an additional 24 CpGs were associated with only environmental factors, while only 3 CpGs were associated with genetic factors alone. Environmental factors associated with methylation were predominantly maternal-adiposity-related (pre-pregnancy body mass index, pregnancy weight gain and maternal glucose levels). Methylation levels at half of these CpGs were also associated with offspring size and adiposity in early childhood. Conclusion Developmental pathways to obesity begin before birth and involve genetic, epigenetic and environmental factors.

Objectives
Genome-wide association studies (GWAS) have indicated that sequence variation in cis-regulatory elements (CRE) plays important roles in common disease risk/trait variation, but identification of these causal variants has remained a major challenge in complex trait genetics. Here, we performed reporter assays for all common variants at the QT interval associated SCN5A GWAS locus, with the goal of identifying the underlying causal variants. Methods A target region of~500kb at SCN5A was defined based on recombination hotspots (rate>10cM/Mb; HapMap) flanking the 5 independent QT interval GWAS hits. Within the target region, all common variants (minor allele frequency >5%) from the 1000 Genomes European ancestry populations in moderate linkage disequilibrium (r 2 >0.3) with any of the 5 GWAS hits were selected. Both alleles of these variants were amplified with flanking sequences and cloned upstream of a minimal promoter driven firefly luciferase gene in pGL4.23. Human cardiomyocyte cells, AC16, were transfected with test constructs and Renilla luciferase vector (for transfection normalization) in triplicate and luciferase assays were performed 24h later. Reporter assays on a subset of variants were repeated for assessing allelic difference in regulatory activity. All cloning and reporter assays were performed in 96-and 24-well plates.

Results
Of a total 121 variants selected, 112 variants in 104 amplicons passed primer design (amplicon size 256-617bp; median 397bp), and we successfully cloned both alleles for 106 variants in 98 amplicons. In reporter assays, compared to empty vector, 24 and 40 amplicons showed enhancer (>2-fold) and suppressor (<0.5-fold) activities in AC16 cells, respectively. Of these only 4 were observed as open chromatin regions in heart tissue in NIH Epigenomics data. Overall, 12 variants showed nominally significant allelic difference (P<0.05) in reporter activity and were repeated with 18 replicates and 7 variants were identified to have repeated significant allelic difference in regulatory activity. Conclusion Independent of the available epigenomic data, which are of limited relevance, an unbiased in vitro reporter screen for CREs overlapping all common variants associated with QT interval at the SCN5A GWAS locus identified 7 common cis-regulatory variants. Our immediate next goals are to a) evaluate the effect of deleting these 7 CREs on SCN5A expression in AC16 cells and b) identify the trans-acting factors regulating their functions.
Objectives Some cancers show a strong tendency to metastasize to bone, a tissue of mesenchymal origin and a prominent site of mesenchymal stem cells (MSC) residing in the stem cell niche. With bone metastasis formation being one of the most detrimental steps in cancer progression, a better understanding of how bone metastases are initially formed is key to successfully targeting bone metastasis of, for example, prostate cancer. Recent reports have suggested that bone-metastasizing cancers may mimic the process of homing of hematopoietic stem cells to their bone niche.

Methods
In order to understand the role of MSC in metastasis formation, we investigated the interaction of primary human bone marrow MSC with established cancer cell lines able to metastasize to bone. With a trans-well migration assay we could show that MSC induced a rapid migration response of prostate and breast cancer cell lines already within two hours after start of the experiment. In order to identify factors stimulating cancer cell migration, MSC cell culture supernatant was separated by size exclusion and ion exchange chromatography. Migratory fractions then were further analyzed by mass spectrometry and antibody array analysis.

Results
With this approach we identified the extracellular matrix proteins type I and type III collagen, fibronectin and laminin 421 as potential drivers of cancer cell migration, which was confirmed by using recombinant proteins. RNAi experiments showed that the cancer cell extracellular matrix receptor beta 1 integrin obviously plays a pivotal role for cell migration. Conclusion From our results we conclude that the extracellular matrix as it is produced by MSC obviously plays a crucial role for cancer metastasis and therefore might be a promising anti-cancer drug target.

Objectives
Trisomy 21 is a model disorder of altered gene expression. We have previously used a pair of monozygotic twins discordant for trisomy 21 to study the global dysregulation of gene expression, without the noise due to genetic variation among individuals (Nature:508; 345-350;2014). The majority of previous studies focused on aneuploidies were conducted οn cell populations or tissues. Our study focusing on gene and allelic expression behaviour of single cells (SC), aims to reveal biological insights regarding the cellular impact of aneuploidy and uncover the mechanisms of gene dosage.

Methods
We estimated the allele specific expression (ASE) from RNAseq of 1000 single cells in different aneuploidies. We used 352 SC fibroblasts (173 Normal and 179 T21 cells) from the pair of monozygotic twins discordant for T21, 166 SC from a mosaic T21, 176 SC from a mosaic T18, 151 SC from a mosaic T8, and 146 SC from a mosaic T13.

Results
In the monozygotic twins, a considerable number of heterozygous sites at the non-chr21 genome showed monoallelic expression (MAE); (Normal: 73.5 % monoallelic in 564,668 observations, and T21: 78.7 % monoallelic in 549,799 observations). There was also considerable MAE for chr21 sites in Normal and, surprisingly, in T21 cells as well (Normal: 63,3 % monoallelic in 5,009 observations, and T21: 72.8 % monoallelic in 6,456 observations). We classified the genes on chr21 in 3 classes according to the level of the aggregate MAE of their corresponding sites (9 monoallelic, 29 intermediate, 2 biallelic). Similar results, i.e. extensive MAE on the supernumerary chromosome genes, were also observed in the other aneuploidies.

Conclusion
We hypothesize that each class of genes contributes in a specific way to the phenotypic variability of Down Syndrome. Our analysis showed that, for genes with monoallelic expression, the abnormal gene dosage induced by the aneuploid chromosome is maybe due to the number of cells expressing the gene. This difference in the fraction of expressing cells could contribute to the development and the variability of phenotypes in aneuploidies. This study provides a new fundamental understanding of the allele specific expression in T21 and other aneuploidies.
Objectives A large number of EBV immortalized lymphoblastoid cell lines (LCLs) have been generated and maintained in genetic/epidemiological studies as a perpetual source of DNA and as a surrogate in-vitro cell model. Recent successes in reprograming LCLs into induced pluripotent stem cells (iPSCs) have paved the way to generate more relevant in-vitro disease models using this existing bio-resource. However the effects of EBV encoded oncoproteins on cellular transcription and function make LCLs a unique biomaterial to reprogramme. Accumulating evidence now provides support that miRNAs play a critical role in transcription factor-induced reprogramming of iPSCs.

Methods
To investigate the role of miRNAs in regulating gene expression and cellular functions during LCL to iPSC reprogramming, we performed a parallel genome-wide miRNA and mRNA expression analysis in six LCLs and their reprogrammed iPSCs. Results A total of 77 miRNAs and 5,228 mRNAs were significantly (FC-abs ≥ 2.0 and FDR ≤ 0.05) differentially expressed (DE) during LCL to iPSC reprogramming out of which 29 miRNAs and 2,317 mRNAs were significantly down-regulated and 48 miRNAs and 2,911mRNAs were significantly up-regulated. The down-regulated miRNAs were highly enriched for LCL specific miRNAs (miR-155, let-7a-i, miR-21, miR-142, miR103, miR-320, miR-146a-b) and the up-regulated miRNAs were highly enriched for iPSC specific miRNAs (miR-302a, miR-302c, miR-371a, miR-302b, miR-302d, miR-372, miR-373miR-92a-1, miR-92a-2, miR-92b, miR-17, miR-20a, miR-18a). Further we performed target prediction analysis for all the significantly DE miRNAs using the miRNA target prediction data bases. The 3,456 genes were predicted to be the targets of the 29 miRNAs that were significantly down-regulated during LCL to iPSC reprogramming. Out of these 3,456 predicted target genes 1,023 were significantly DE during LCL to iPSC reprogramming. For the 48 miRNAs that were significantly up-regulated during LCL to iPSC reprogramming 5,063 target genes were predicted out of which 1,462 were significantly DE during LCL to iPSC reprogramming.
The significantly DE genes that were also the predicted targets of the significantly down or up regulated miRNAs were further analyzed for functional annotations and pathway analysis using Ingenuity Pathway Analysis Platform.

Conclusion
In summary, our analysis identifies DE miRNAs and their DE target genes and a global role of miRNAs in broad resetting of cellular transcriptome and function during LCL to iPSC reprogramming.

Objectives
Common sequence variation in cis-regulatory elements (CREs) are the suspected etiological causes of complex disorders. We examined all common (>10% minor allele frequency) non-coding variants within a~153kb locus surrounding the gene for receptor tyrosine kinase RET, which is most commonly mutated in Hirschsprung disease (HSCR or congenital aganglionosis), a form of functional intestinal obstruction in neonates (1 in 5,000 live births). We hoped to find all causal non-coding polymorphisms disrupting enhancer function leading to the disease.

Methods
We used human and mouse fetal gut at relevant developmental time points for transcriptional profiling, ChIP assays, transgenic enhancer assays and siRNA mediate knockdowns of relevant transcription factors.

Results
We demonstrate that: (i) the three polymorphisms residing in 3 distinct enhancers that increase risk of the disease by 4-, 2-and 1.7-fold. Haplotypes for these three independent variants display wide variation in risk. (ii) the three CREs are Ret enhancers with distinct temporal activities during mouse gut development; (iii) the CREs are bound by the transcription factors Rarb, Gata2/3 and Sox10, respectively, each developmentally expressed concordant with its cognate enhancer activity; (iv) variants in these CREs lead to their loss of activity and reduce Ret expression; (v) Ret is a positive feedback regulator of Sox10 and Gata2/3 transcription; and, (vi) additional feedback interactions affect its ligand Gdnf, co-receptor Gfra1 and signal terminator Cbl.

Conclusion
These results explain how individually common, small effect noncoding polymorphisms can lead to large genetic effects in HSCR, since transcription attenuation of Ret from enhancer mutations are amplified through its auto-regulation. These results implicate RET as a key rate limiting step in early enteric nervous system (ENS) development and explains why >95% of HSCR cases have at least one RET loss-of-function allele. More generally, the phenotypic impact of a complex disorder can only be understood by assessing gene effects in the context of their gene regulatory networks.

Objectives
In individuals presenting with undifferentiated phenotypes such as developmental delay, hypotonia, and seizures, the list of differential diagnoses is often very long and includes metabolic/neurometabolic, genomic, and other Mendelian disorders. Here we want to demonstrate the utility of untargeted metabolomic profiling to screen for a wide range of neurometabolic disorders.

Methods
Untargeted small molecule metabolomic profiling was performed as described previously [1] on plasma samples from 12 patients suspected to have a neurometabolic disorder with a presentation of seizures, developmental delay and hypotonia.

Results
We identified 5 different neurometabolic disorders in these 12 patients. We observed elevations of 3-methoxytyrosine and decreased levels of dopamine and vanillylmandelate in AADC deficiency, elevations of 2pyrrolidinone in ABAT deficiency, elevations of succinyladenosine in ADSL deficiency, increased citrate in citrate transporter deficiency, and elevations of imidazole propionic acid, cis and trans-urocanate in urocanase deficiency. The perturbations in the metabolomic profiles of plasma from these patients are unique, specific and not previously seen in over 300 other samples analyzed as normal controls or for other indications.

Conclusion
The standard diagnostic test for AADC, ABAT, and ADSL deficiency is CSF neurotransmitter analysis, while testing for urocanase deficiency requires an enzyme activity assay from a liver biopsy. These cases demonstrate the ability of untargeted metabolomic profiling for the functional confirmation of pathogenicity of VUS found via WES; moreover, disorders for which there is no biochemical testing or where testing is only available on CSF are able to be diagnosed in a plasma sample. This also demonstrates the utility of metabolomic profiling alone to screen for a wide range of neurometabolic disorders.

Objectives
Alzheimer's disease (AD) is the most common progressive neurodegenerative disease and represents a major cause of disability for elderly patients. DNA methylation-are increasingly seen as playing an important role in AD development. However its causal mechanisms remain unclear. Recent studies indicate that AD develops essentially as a result of dysfunction of molecular networks. Our purpose is develop large-scale causal methylation networks to uncover the mechanism of AD development.

Methods
We propose to use causal graphs as a major concept and a general framework for causal methylation network analysis and develop "score and search"-based methods for exact learning causal graphs of methylation networks to find the best-scoring structures for a given methylation dataset. Specifically, we develop novel functional structural equations for modeling methylation networks and use integer programming to search the network with optimal score.

Results
The proposed methods were applied to AD data with 460045 CpG sites from 748 samples. At the first stage, the methylation data of 168 gene from the pathway 'Alzheimer's disease were used to create a causal network describing the connection among the methylation sites between these genes. According to the current result, 148 gene was matched and tested in the model. We identified a largest connected causal methylation network with 47 nodes and 96 edges. Most genes were confirmed to play an important role in the AD development from the literature.

Conclusion
The proposed methods provide a highly flexible general framework for causal methylation network analysis and provide more rich information than co-methylation network. The exact learning algorithms will guarantee to find optimal solutions and hence provide accurate estimations of causal graphs of methylation networks. The causal methylation networks are able to uncover the mechanism of AD development.

Disclosure of interest
None declared.

O11
A microRNA signature identifies subtypes of triple-negative breast cancer and reveals MIR-342-3P as regulator of a lactate metabolic pathway A. Hidalgo-Miranda 1 , S. Romero-Cordoba 1 , S. Rodriguez-Cuevas 2 , R. Rebollar-Vega 1 , E. Tagliabue  Objectives Triple negative breast cancer (TNBC) represents a challenging tumor type due to their poor prognosis and limited treatment options. It is well recognize that clinical and molecular heterogeneity of TNBC is driven in part by post-transcriptional regulators such as miRNAs. To stratify TNBCs, we profiled 1050 miRNAs in 132 adjuvant TNBC tumors and 40 tumors from other immunophenotypes using an Affymetrix microarray platform. Methods A NMF clustering analysis allowed us to identify 4 TNBC subtypes featuring unique miRNA expression patterns, disease free and overall survival rates and particular gene ontology enrichments. Our agglomerative approach was cross-validated by using two other clustering algorithms. 3 cell line models were classified according to our miRNA signature, recapitulating two different miRNA subgroups. The TNBC tumors were compared against other phenotypes identifying differentially expressed miRNAs to define interesting miRNAs for further functional analysis.

Results
We found low expression levels of miR-342-3p in TNBC tumors compared with other breast cancer phenotypes, and this down-regulation characterizes one of our miRNA subgroups with high risk to relapse. To characterize its functional role, miR-342-3p was transiently transfected in the cell line MDA-MB-468, showing a decrease in cell proliferation, viability and migration rates. A gene expression profile revealed 140 altered mRNAs, from which 35 are potential direct targets of miR-342-3p defined by an in-silico analysis. The monocarboxylate transporter 1(MCT1), was confirmed as one target of miR-342-3p by a luciferase assay and western blot analysis. MCT1 repression by the miRNA promotes lactate efflux changes in the tumor cells, reflected in the accumulation of exogenous lactate and the increase in levels of extracellular endogenous lactate together with a decrease level of intra and inter cellular glucose concentration.

Conclusion
These data suggest a metabolic change that favors a more glycolytic environment, which lead to a glucose deprivation context that may contribute to the reduction in proliferation, viability and migration capabilities already described.

Objectives
We aim to find genes that are frequently deregulated in cancer and thus can be useful as diagnostic markers for early detection, and potentially as therapeutic targets. We focus on biomarkers with pancancer potential that can be applicable to multiple cancer types.

Methods
We used the Cap Analysis of Gene Expression (CAGE) profiles of 225 cancer cell lines and 339 normal primary cells from FANTOM5 project. CAGE is a 5′ sequence tag technology that enables promoterlevel expression analysis and can be used to estimate the activity of enhancers from bidirectional transcription of enhancer RNAs. As a complementary data set, we used RNA-seq data from 14 tumor types profiled by The Cancer Genome Atlas (TCGA). In both data sets (FANTOM5 and TCGA), we performed cancer vs. normal differential expression analysis in all cancer types.

Results
We identified a set of pan-cancer markers (of both coding and noncoding transcripts) that are recurrently perturbed in both the cancer cell lines (FANTOM5) and clinical tumors (TCGA). The FANTOM5 CAGE data provided novel insights into cancer transcriptome. We used the genomic location of the CAGE TSSs to show that promoters that overlap repetitive elements (especially SINE/Alu and LTR/ERV1 elements) are often upregulated in cancer. Specifically, a little known repeat family, REP522 (~1.8Kb in size, largely palindromic, unclassified interspersed repeat), was strongly enriched for the most cancer-activated promoters. Here we present previously un-published, follow-up results that detail the REP522 activation in cancer. Finally, we present 90 enhancers that are activated in cancer cell lines. With ENCODE ChIA-PET data, we linked 16 of those enhancers to promoters of known cancer genes. Conclusion Our transcriptome analysis identified candidate biomarkers with pancancer potential and provided new insights into enhancers and repetitive elements that are recurrently activated in cancer. Objectives Disruption of gene regulation is thought to play major roles in carcinogenesis and tumour progression. Here, we characterize the mutational profiles of diverse transcription factor binding sites (TFBSs) across 1,574 completely sequenced cancer genomes encompassing 11 tumour types. We assess the relative rates and impact of mutation at the binding sites of 87 different transcription factors (TFs) by comparing the abundance and patterns of single base substitutions within putatively functional binding sites to matched control sites.

Methods
To detect putatively regulatory binding sites in the genome, we used a combination of computational prediction and experimental data. Position weight matrices for 118 transcription factor binding motifs were used to find TFBS motif matches in the genome. We intersected these motif matches with experimentally defined open chromatin regions to define putatively functional TFBSs. Motif matches not occurring within open chromatin were used as control, putatively nonfunctional sites. Comparisons between these functional and control sites underlie our methods, and we develop novel metrics to assess the relative rates and functional impact of cancer mutations at putatively funcitonal regulatory sites.

Results
We observe a strong and significant excess of mutations at functional binding sites across TFs, and show that the substitutions that accumulate in cancers are often more disruptive than those that are tolerated as germline variants. Putatively functional CTCF binding sites suffer an exceptionally high mutational load in cancer relative to control sites, and those involved in the architecture of higher order chromatin structures are the most highly mutated. The mutational load at CTCF-binding sites appears to be dominantly determined by replication timing and the mutational signature of the tumor sample in question, suggesting that selectively neutral processes underlie the unusual mutation patterns seen at CTCF sites across tumor types.

Conclusion
We show that mutations at active TFBSs are common in tumours, they appear to accumulate largely unchecked by selective processes and are independent of mutations in coding sequences, exhibiting distinct rates among tumor types. Our study thus underlines the functional importance and fragility of the regulatory genome in cancer.

Disclosure of interest
None declared.

O14
Exome sequencing provides evidence of pathogenicity for genes implicated in colorectal cancer E.

Objectives
Next generation sequencing studies have revealed genome-wide structural variation patterns in cancer, such as chromothripsis and chromoplexy that do not engage a single discernable driver mutation, and that currently have no clinical relevance. We aimed at a detailed molecular characterization of one of these genomic configurations, the tandem duplicator phenotype (TDP).

Methods
We combined whole genome sequencing (WGS) data from 277 human genomes representing 11 cancer types and devised a robust genomic metric able to identify cancers with a chromotype called tandem duplicator phenotype (TDP) characterized by frequent and distributed tandem duplications (TDs).

Results
Enriched only in triple negative breast, ovarian, endometrial, and liver cancers, TDP tumors conjointly exhibit TP53-mutations, low expression of BRCA1, and increased expression of DNA replication genes pointing at re-replication in a defective checkpoint environment as a plausible causal mechanism. The resultant TDs in TDP augment global oncogene expression and disrupt tumor suppressor genes. Importantly the TDP strongly correlates with cisplatin sensitivity in both triple negative breast cancer cell lines and primary patient-derived xenografts.

Conclusion
We conclude that the TDP is a common cancer chromotype that coordinately alters oncogene/tumor suppressor expression with potential as a marker for chemotherapeutic response.

Disclosure of interest
None declared.

O16
Modeling genetic interactions associated with molecular subtypes of breast cancer B. Ji, A. Tyler, G. Ananda, G. Carter The Jackson Laboratory, Bar Harbor, ME, USA Correspondence: G. Carter -The Jackson Laboratory, Bar Harbor, ME, USA Human Genomics 2016, 10(Suppl 1):O16

Objectives
The characterization of mRNA-expression subtypes in breast cancer facilitates genomic and genetic studies to identify biological processes that drive distinct molecular subtypes and elucidates the potential feasibility of subtype-specific drug targets. However, such therapies tend to have limited efficacy, often due to unpredicted compensation in the network of mutations. Polygenic models that account for multiple somatic mutations and their interactions can potentially improve target selection and provide a more detailed view of tumor genetic architecture.

Methods
We addressed this problem with a multi-trait genetic interaction analysis of copy-number variation and gene expression data from breast cancer samples in The Cancer Genome Atlas. Modules of coexpressed genes were derived and assessed for biological function and genetic association with mutations in oncogenes and tumor suppressors. Summary module phenotypes with pleiotropic associated loci were simultaneously analyzed to infer direct genetic effects as well as effects mediated by genetic interactions for each module.

Results
We observed widespread evidence of genetic redundancy, in which two mutations combine to yield a less than additive effect that is similar to either mutation in isolation. In addition, we also identified interacting mutations that combinatorially associate with distinct modules and subtypes in a non-additive manner. These somatic mutant combinations were often predictive of molecular subtypes when single mutations were not.

Conclusion
Accounting for interactions among somatic mutations in tumor samples reveals high genetic redundancy and complex regulatory hypotheses for breast cancer subtypes. Our work demonstrates how integrative genetic and genomic analysis can be used to generate more precise hypotheses for tumor genetics, which may be used to prioritize therapeutic targets for robust tumor suppression.

Disclosure of interest
None declared.

O17
Recurrent somatic mutation in the MYC associated factor X in brain tumors H. has not yet been reported. Here we report discovery of a novel recurrent somatic mutation in MAX in brain tumors and study its effects on the development and progression of tumors.

Methods
We found a mutation on Arg 51 residue to Glu in MAX gene in a patient with bilateral thalamic pediatric astrocytoma in which the primary tumors (left and right thalamus) had nearly identical mutation profiles except for the presence of the MAX R51Q only in one. We used this unique opportunity to study the effects of this mutation on the progression and development of brain tumors. We performed differential expression on these samples to find the pathways affected by this mutation. Using ChipSeq we studied changes in the chromatin conformation in genes regulated by this network. We used CD experiments, to study how this mutation affects the affinity between Max and other proteins in this family and with DNA.

Results
We screened our dataset and found 7 cases in 180 HGAs exome sequenced by our group (3.8%) with this mutation. We also identified 14 cases in published datasets. We found that this mutation always appears later in tumor development in subclonal fashion and is accompanied by at least one driver such as H3 K27M. Our differential expression and ChipSeq experiments revealed lack of a global effect of this mutation but specific effects on groups of genes involved in some pathways such as apoptosis.
We also demonstrate that this mutation has no effect on the binding efficacy between proteins in its regulatory network, but a Max R51Q homodimer binds less efficiently to nonspecific DNA than its wild type. It however, only affects the binding between Myc/Max heterodimer to DNA in E-boxes.

Conclusion
We identify MAX as a new cancer gene, particularly relevant to brain cancer.
Our results show the possible effects of MAX mutation in promoting tumor progression and development. It also suggests the effect of this mutation on the spread of the tumor. These findings shed new light on the mechanisms underlying cancer progression and the involvement of MYC signalling in development of brain tumors which, in turn, can point us towards new targets for therapeutic approaches.

Objectives
In 2015, we demonstrated that a strong family history of BRCA related tumors portends a better prognosis in metastatic pancreatic cancer patients. We now investigate if this holds true for more recent patients treated with standard-of-care FOLFIRINOX (FNX) or Gemcitabine/nab-paclitaxel (GA). We hypothesize that targeted sequencing of these tumors for DNA repair pathway aberrations will better predict outcomes than the surrogate marker of family history, which may be subject to patient bias.

Methods
We identified patients with de novo stage 4 pancreatic cancer initially treated at MD Anderson Cancer Center with first-line FNX or GA. We excluded patients with prior surgical resection (bypass was allowed) or radiation as initial therapy, and patients with unknown family history. Survival analysis was performed using the Kaplan-Meier method.

Results
We identified 153 patients initially treated with FNX and 80 patients treated with GA. Median age of the entire cohort was 62 years (36-84), 58% were male. Median OS was 286 and 295 days, respectively. Approximately 5% of patients had a family history of 3 or more BRCA tumors (breast, ovarian, prostate, pancreas). Median OS for these patients was 469 days, as compared to 285, 268, and 296 days for patients with 0, 1, and 2 affected family members. Median survival in patients with 3+ family members affected was 463 days and 511 days for patients on FNX and GA respectively (95% CI 240-636d, 0-1092 d). For patients with 0-2 such family members, median OS was 283 and 268 days, respectively. As expected, ECOG 0-1 and the absence of liver metastases were associated with longer survival. We identified 126 of 153 FNX patients and 51 of 80 GA patients with pathology specimens available for targeted sequencing.

Conclusion
As in our earlier report, we see a trend towards increased survival in patients with 3 or more family members with BRCA related tumors. However, the small number of these patients precludes a definitive assessment. We believe that targeted sequencing of DNA repair pathway and associated genes will better elucidate the mechanism of survival benefit over biased family history.

Objectives
The DDIT4 gene (DNA-damage-inducible transcript 4) encodes a protein related to adverse environmental conditions, whose action is the inhibition of mTOR. In a recent work we found DDIT4 levels was associated with the outcome in triple negative breast cancer (J Clin Oncol 33, 2015 (suppl; abstr 1097)). There are not previous reports relating DDIT4 with prognosis of cancer patients. Our aim in this study was to explore the influence of this gene in several types of malignant tumors.

Methods
We evaluated the influence of DDIT4 expression in the outcome (either, disease-free survival or progression-free survival or overall survival

Objectives
The hierarchical folding of genomic DNA within the nucleus is closely related with transcriptional regulation. Recent chromosome conformation studies have suggested that mammalian chromosomes are structured into tissue-invariant topologically associating domains (TADs) where the DNA within a domain is interacting more frequently than with regions in other domains. Genes within the same TADs represent similar geneexpression, histone-modification profiles. Therefore regions separating different TADs (boundaries) have important roles in reinforcing the stability of these domain-wide organizations. TAD boundary disruptions in human limb malformations and cancer lead to dysregulation of certain genes, due to de novo promiscuous enhancer exposure to promoters.
Here we sought to identify relationship between genomic architecture and genomic alterations in human cancers.

Methods
We utilized approximately 200 thousand somatic genomic alterations (deletions, inversions, duplications) and more than 34 million somatic mutations from 2575 high-coverage whole genome sequencing data across 45 different cancer studies with paired normal samples. We integrated mutations, gene expression and structural alterations with TAD boundaries that we have identified from 5 different human cell lines, representing three different germ layers.

Results
Our analysis revealed a strong correlation between the mutational landscape and the TAD organization of the genome. In addition, we found that TAD boundaries inflicted structural alterations that not only affected nearby gene regulation but also the distribution of mutations in human cancers.

Conclusion
Structural alterations affecting the spatial organization of the human genome, could lead to dysregulation of genes as well as aberrant mutation distributions in human cancers.

Disclosure of interest
None declared. Objectives Precision medicine initiatives in oncology focus on specific genetic aberrations as predictive biomarkers for targeted therapies. Nextgeneration sequencing technologies have driven a projectile shift in patient management through somatic tumor profiling. Due to the rapid pace of this ensuing momentum, it is difficult to grasp such a dynamic landscape. Therefore, an analysis of the targeted therapy landscape was conducted and methods employed are disseminated to foster interoperability among datasets.

Methods
A Clinical Knowledgebase (CKB) was created to capture and rapidly retrieve therapeutic information related to patient molecular aberrations. One requirement was the development of a drug class controlled vocabulary to categorize drugs relative to their target specificity, including both pan-level and more gene specific targeted drugs. Additionally, to support capture of combination therapies, one or more single drug entries can be concatenated to a therapy. Drug classes are annotated to molecular variants and therapies are annotated to complex molecular profiles. Using the JAX-CKB, an analysis was conducted on the number and types of targeted therapies for solid tumors associated with 358 genes and in actively recruiting clinical trials.

Results
The CKB drug class ontology currently contains 198 terms, consisting of 113 parent and 83 child terms. There are 1006 targeted therapies in CKB and of these, 59 are FDA approved. Pan drug classes include PI3K inhibitors and mTOR inhibitors, which contain 34 and 41 individual drugs within each class, respectively. The drug class VEGFR inhibitors (Pan) has the highest number of hits in actively recruiting clinical trials, and 19 drug classes, including EZH2 inhibitor and p53 activator, are represented in a single solid tumor clinical trial. Furthermore, the most common drug in solid tumor clinical trials is Bevacizumab.

Conclusion
Consistency and interoperability of knowledgebases to support clinical next-generation sequencing is pivotal. The JAX-CKB, described here, is built upon controlled vocabularies and ontologies to achieve this mission. Methods on the design and build are shared to foster collaborative processes in this rapidly evolving NGS domain. Furthermore, analysis of content regarding targeted therapies provides an objective view of clinical trial research investigating targeted therapies in solid tumors.

Objectives
Basal cell carcinoma of the skin (BCC) is the most common malignant neoplasm in humans. BCC is primarily driven by aberrant activation of the Sonic Hedgehog (Hh) pathway. However, its extensive phenotypical variation remains to be explained.

Methods
The genetic profiling of 293 BCCs revealed the highest mutation rate observed in cancer (65 Mutations/Mb), with strong prevalence of UVlight signature mutations.

Conclusion
The functional analysis of the novel tumorigenic driver mutations in MYCN, PTPN14 and LATS1 demonstrates their relevance in BCC tumorigenesis and provides an expanded molecular understanding of BCC.

Disclosure of interest
None declared.

O23
Identification of differential biomarkers of hepatocellular carcinoma and cholangiocarcinoma via transcriptome microarray meta-analysis S. Likhitrattanapisal Department of Biology, Faculty of Science, Mahidol University, Bangkok, Thailand Human Genomics 2016, 10(Suppl 1):O23 Objectives Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are the members of hepato-biliary diseases. As both HCC and CCA arise from similar cell types, they often exert high levels of similarity in terms of phenotypic characteristics, thus leading to difficulties in HCC and CCA differential diagnoses. In this study, a meta-analysis was performed on HCC and CCA transcriptome microarray data for the purpose of investigating differential transcriptome networks and potential biomarkers of CCA and HCC. Methods Raw data from 9 HCC and CCA gene expression microarray datasets, consisting 1,185 samples in total, were methodologically compiled and analyzed. For determining differentially-expressed genes in the cancers, gene expression were compared between cancer and its respective normal samples (HCC vs Normal Liver and CCA vs Normal Bile Duct) using t-test and k-fold validation (P < 0.05).

Results
Comparing to normal samples, 226 differentially-expressed genes were specifically observed in HCC, 249 genes in CCA, and 41 genes in both. Gene Ontology and KEGG pathway enrichment analyses showed different patterns between functional transcriptome networks of HCC and CCA. Cell cycle and glycolysis/gluconeogenesis pathways were specifically affected in HCC whereas complement and coagulation cascades as well as glycine, serine and threonine metabolism were predominantly presented in CCA.

Conclusion
Our meta-analysis revealed different dysregulation in transcriptome networks between HCC and CCA. Some genes in these networks were selectively discussed in the context of HCC-CCA transition, unique characteristics of HCC and CCA, and their potentiality as HCC/CCA differential biomarkers. Objectives Clinical genetic testing is rapidly evolving with the introduction of next-generation sequencing (NGS) however questions remain about these new tests. First, can NGS methods be deployed that deliver equal or improved performance vs. traditional methods on the full spectrum of (often complex) disease causing variants? Second, do expanded NGS tests provide medical benefits which outweigh the increased uncertainty that naturally follows from testing more genes in more patients? In recently published work [1,2] we tested a large panel of cancer risk genes by NGS in a clinically representative population to evaluate these questions. Here we expand upon that work with additional cases including patients with expanded indications for testing and complex presentations.

Methods
We tested a large panel of 25-32 cancer risk genes by NGS in a representative cohort of over 1000 patients meeting current medical guidelines for BRCA1/2 testing. Traditional genetic test results were available for the patients for comparison. Using an interpretation system (Sherloc) based on ACMG 2015 guidelines and employing only publicly available data, variants uncovered by NGS were classified. We established a uniform algorithm based on current practice guidelines to recommend management actions for the non-BRCA1/2 positive individuals, and we evaluated which of these recommendations would represent changes in management above and beyond any recommendations based on personal and family history alone.

Results
We find 100% concordance with traditional methods on both sequence and copy-number alterations using a battery of 5 calling algorithms and associated biochemistries., we find 99.8% concordance with BRCA1/2 classifications produced by a different laboratory that uses a large proprietary database. Finally, we find that 52% of genetic test results positive for genes other than BRCA1/2 would warrant consideration of a change in care for mutation-positive patients under current medical practice guidelines.

Conclusion
In appropriately referred patients, multi-gene panel testing yields clinically relevant findings with potential management impact for substantially more patients than does BRCA1/2 testing alone.

O25
Correlation with tumor ploidy status is essential for correct determination of genome-wide copy number changes by SNP array T. L. Objectives Neuroblastoma, the most common extra-cranial solid tumor in the pediatric population, is a histologically and clinically heterogeneous neoplasm. Tumors characterized only by whole chromosome changes tend to act favorably, whereas tumors with MYCN gene amplification and/or segmental chromosomal aberrations have poor outcomes. Given the clinical relevance, our aim was to verify the accuracy of OncoScan FFPE SNP Array (Affymetrix) in assessing genome-wide copy number changes in tumor samples by comparison to other tumor ploidy testing methods. Methods 39 neuroblastic tumors from 38 patients were analyzed using the OncoScan FFPE SNP Array at a pediatric hospital. Tumor slides were macrodissected to increase tumor purity, genomic DNA was isolated and arrays hybridized according to manufacturer's protocol. Data was analyzed using the OncoScan Console and results viewed using Chromosome Analysis Suite (ChAS) and OncoScan Nexus Express. Copy number results determined by SNP array were compared to ploidy results obtained by karyotype analysis and/or flow cytometry. Additionally, chromosome 1 and 2 aneuploidy data were used as a surrogate ploidy marker in cases where cytogenetics and flow cytometry were unavailable.

Results
Data were obtained for 33 of the 39 samples. Review showed that 3 of the 33 samples required recentering of the tumor ploidy baseline. Two samples from 2 lesions in one patient showed widely discordant copy number calls by the software, with one assigned a near tetraploid status and the other a near diploid status. Karyotype analysis confirmed a near tetraploid state. Correlation by karyotype, flow cytometry or chromosome 1 and 2 aneuploidy revealed an additional 4 discordant cases (total of 5/33 cases or 15%).

Conclusion
Despite complex algorithms used by the OncoScan software to assign copy number calls, in 15% of the analyzed cases a 2nd method was necessary to correctly assign tumor ploidy baseline. The complex chromosomal copy number changes present in tumors, in addition to tumor impurity, heterogeneity, and poor sample quality, can challenge the software's ability to correctly assign ploidy state. Our results demonstrate that a second independent method may be necessary in complex tumor cases to correctly assign ploidy that truly reflects tumor biology and that may be necessary for correct patient management.

Disclosure of interest
None declared. Objectives Structurally complex loci underlie many diseases. These loci can be very challenging to resolve by currently available methods such as karyotyping, clinical array, PCR-based tests, and NGS. Next-generation mapping by BioNano Genomics Irys® System offers a high-throughput, genome-wide method able to interrogate genome structural differences hundreds of kilobase pairs and span interspersed and even long tandem repeats making it ideally suitable for elucidating the structure and copy number of complex regions of the genome, such as complex pseudogene and paralogous gene families. Clinically relevant regions often contain genes with paralogs and other complex repetitive structures complicating the interpretation of data and diagnosis of disease. We present several examples of genetic loci that can be easily interrogated with genome map data including tandem repeats, paralogous gene families, and loci flanked by segmental duplications. Methods Some open reading frames or entire genes are randomly amplified with variable copy number such as tRNAs, kringle IV, and D4Z4. The LPA gene contains variable copies of a repeat, kringle IV, that results in different lengths of the resultant Lp(a) protein; related to coronary heart disease, cerebrovascular disease, atherosclerosis, thrombosis, and stroke. Tandem repeat is D4Z4, associated with facioscapulohumeral muscular dystrophy (FSHD), with a low copy number (<10 units), occurring in 95% of FSHD cases.

Results
We show that the Irys System can accurately measure the copy number of the kringle IV domain and D4Z4. A second class of complex structural variation are those that involve genes with paralogs such as amylase and UGT2B17, two genes whose copy number have been shown to be involved in human health. We show deletions of UGT2B17 in a family trio and > 10 different structures at the Amylase region. The third class of genomic variation are those flanked by segmental duplications, especially important because spontaneous rearrangements are common between paralogous segmental duplications causing copy number aberrations and translocation, thus resulting in developmental disorders, such as the 22q11.2 deletion syndrome mediated by segmental duplication rearrangements.

Conclusion
We show the assembly of the region, including the normal and pathogenic alleles, using molecules that span and disambiguate the structure of the segmental duplications. Objectives To identify the genetic determinants of Pulmonary Arterial Hypertension (PAH) in a cohort of pediatric PAH patients.

Methods
We performed whole-exome sequencing (WES) in a cohort of 60 probands with PAH and family members when available (180 total individuals) without a molecular diagnosis after most of the series was screened for mutations in BMPR2. In addition, we performed WES in additional 118 singleton cases. We screened all samples for variants in known PAH associated genes and performed trio-based analysis to identify novel candidate PAH genes.

Results
We identified known and novel mutations in the known PAH genes. In addition we identified novel truncating variants in TBX4 occurring de novo or inherited from an asymptomatic parent in 5 patients and a de novo predicted deleterious nonsynonymous variant in one additional patient.
TBX4 is a transcription factor of the T-box gene family. It is expressed in a variety of tissues during early mouse development including the atrium of the heart, the limbs, and the mesenchyme of the lung and trachea. TBX4, jointly with TBX5, has been shown to interact with FGF10 during lung growth and branching. Mutations in TBX4 have been previously reported to cause small patella syndrome, an autosomaldominant skeletal dysplasia characterized by patellar aplasia or hypoplasia. A study in 2012 [1] identified an association of TBX4 mutations with PAH in 6 patients.

Conclusion
We identified 6 different deleterious variants in TBX4 (2 inherited and 5 de novo) in our initial cohort of trios where patients were ascertained for primary pulmonary arterial hypertension, accounting for~10% of the probands in this series. Subsequently we confirmed this association in additional 4 singleton cases, including a patient with a large intragenic microdeletion of TBX4. Our results confirm the role of TBX4 as an important cause of hereditary PAH, accounting for~5% of our whole PAH cohort.

Methods
We performed targeted Nex Gen sequencing of the MCDR1 region (870kb) in 8 affected individuals from 3 families representing 3 different haplotypes affected with chromosome 6 linked NCMD (MCDR1).
In addition to our original 11 MCDR1 families recently published (141 total subjects), we now have an additional cohort of 23 families with the NCMD phenotype available for study (total of 367 subjects, 32 families).

Results
We initially found 14 rare variants spanning 870kb of the diseasecausing allele. One of these variants (V1, ch6:1000400906) was absent from all published databases and all 261 controls, but was found in a total of 13 NCMD kindreds. This variant lies in a DNase 1 hypersensitivity site (DHS) upstream of both the PRDM13 and CCNC genes. Sanger sequencing of 1 kb centered on V1 was performed in the remaining NCMD probands, and 2 additional novel single nucleotide variants (V2, ch6:10000987, in 6 families and V3, ch6:100041040 in 1 family) were identified in the DHS within 134 bp of the location of V1. A complete duplication of the PRDM13 gene was also discovered in a single family (V4). The 4 mutations V1 to V4 segregated perfectly in the 118 affected and 33 unaffected members of the 21 NCMD families.

Conclusion
We identified 4 rare mutations in a non-coding region, each capable of arresting human macular development by causing over expression of PRDM13. Additional families with the NCMD phenotype continue to support that these mutations are causative of MCDR1 / NCMD. To identify the causative variant(s) and gene(s) of rare Mendelian phenotypes by the re-analysis of unsolved whole exome sequecing (WES) data.

Methods
To address some of these cases, we have incorporated maternal and paternal imprinting analysis and polygenic analysis to the PhenoDB Variant Analysis tool. We also analyzed WES data from 1063 samples for rare, functional variants in known imprinted genes, in the genes on pseudoautosomal regions, genes that escape X-inactivation, and genes on chromosome Y. To facilitate data sharing as well as improve the search for patients or model organisms with variants in specific candidate genes we have also been adding capabilities to GeneMatcher (www.genematcher.org). In GeneMatcher there is an option to match based upon OMIM® number, genomic location and, as of October 2015, on phenotypic features. As part of the Matchmaker Exchange (MME) (http://matchmakerexchange.org/), we have also developed an API that was implemented in August 2015 and allows the GeneMatcher users to submit their data to query Phenome-Central and/or DECIPHER. Also, as part of the MME we have been working with other matchmaker databases on the API implementation to connect them to GeneMatcher and have been working on the version 2.0 of the API that will allow for more detailed queries.

Results
We found that the genes in the pseudoautosomal regions are not captured by the Agilent SureSelect v4 baits that we used to sequence these samples. The analysis of variants in the genes on chromosome Y identified 52 rare functional variants and the analysis of variants in the 242 imprinted genes identified 4,337 rare functional variants. These variants are being further evaluated to define causality. As of December 2015, 3,568 genes were submitted to Gene-Matcher by 984 individuals from 48 countries and 1252 matches (60 matches with PhenomeCentral and 34 matches with DECIPHER).

Conclusion
The GeneMatcher approach has enabled collaborations and the description of novel Mendelian phenotypes and novel Mendelian genes like SPATA5, HNRNPK and TELO2. We expect that further use of Gene-Matcher and other MME matchmaker databases will enable many new gene/phenotype connections and that the full impact this approach will be revealed in the published literature over the next years.

Disclosure of interest
None declared. Objectives At its inception in 2011 the Baylor-Johns Hopkins Center for Mendelian Genomics (BHCMG), as one of three NIH funded Centers for Mendelian Genomics (CMGs), began its efforts towards: i) novel gene/ mutation discovery, ii) elucidating the molecular bases of disease, iii) understanding the genetic susceptibility to disease traits, and iv) determining the genetic/genomic architecture of disease. Collectively the CMGs have sequenced~19,000 patient samples in collaboration with more than 500 investigators from 36 countries in the past four years. The BHCMG has learned many lessons from its contribution of 5,200 exomes ranging in 475 phenotypes and presented in 82 publications.

Methods
The Human Genome Sequencing Center (HGSC) at the Baylor College of Medicine has generated 46 TB of whole exome sequencing (WES) data using the HGSC-VCRome capture reagent and now includes 'Spike-in PKv2' to capture more difficult regions and additional gene targets. The HGSC-VCRome capture reagent, along with a multiplex strategy and use of full-length blocking oligos employed for hybridization, has yielded 7.7Gb of data per exome providing a coverage of 96% at 20X or greater. The Spike-in PKv2 reagent is comprised of 3,643 additional unique gene targets derived from GeneTests, OMIM, selected cancer genes and Baylor Miraca Genetics Laboratory positive cases. The addition of this reagent converts >700-800 genes from partially covered to fully covered at ≥ 20X coverage.

Results
Success rates in this program have varied by phenotype and cohort collections ranging from 37% to 85%. The BHCMG has established valuable sample acquisition approaches and resources, enhanced sequencing methodology, curated a well-characterized phenotype-rich genetic database enabling genotype/phenotype relationships and encouraged collaborative efforts (i.e. GeneMatcher) to implicate 491 disease genes including 192 novel, 152 known and 147 phenotypic expansion genes.

Conclusion
Each discovery has shown the diagnostic capabilities in using WES and has taught lessons in disease mechanisms that continue to drive investigation into those cases that remain unsolved.

Disclosure of interest
None declared.

O31
Using read overlap assembly to accurately identify structural genetic differences in an Ashkenazi Jewish Trio Objectives Accurately identifying genetic differences between individuals or within samples taken from the same individual (tumor with normal control) is important to understanding the etiology of diseases, particularly for disease areas where large structural changes in the genome have been associated with the disease, such as neurological conditions, cardiological conditions and cancer. In clinical practice, identifying a previously uncharacterized de novo SV in an offspring that could be causing a condition is challenging with current methods that often have high false discovery rates.

Methods
Here, we present Biograph Anchored Assembly (BAA), an SV caller using whole read overlap assembly of reads that do match the reference exactly. In a previous study with next-generation sequencing of the reference individual HS1011 (English et al. (2015)), the method has been shown to have high sensitivity compared to other SV callers and a false discovery rate of less than 5%. The method is based upon the BioGraph data storage format (BAF). The BAF is a specialized index of the read overlap graph of a genome that can be queried up to one million times a second. Querying by both coordinate and sequence is particularly applicable to SV typing.

Results
Using BAA on a trio sequenced by the Personal Genome Project (PGP), the BAA variant caller detected a 3.4kb insertion inherited in the offspring that matched an alternate allele assembly now in GRCh38. The breakpoint and sequence of the insertion were reported. The resolution of this inserted sequence allowed for five SNPs and an indel that were inherited from the father and a single SNP inherited from the mother to be distinguished in the offspring.

Conclusion
This level of resolution and accuracy in calling allows for structural variants, and even differences between structural variants, to be compared across individuals. This is important both for understanding the etiology of disease in larger studies as well as identifying de novo variants in an offspring in a clinical setting. Here, we further present results from 100 HiSeq X samples sequenced at 30x, including multiple classes of structural variants and multi-sample classification of shared breakpoints.

O32
Legal interoperability: a sine qua non for international data sharing A. Objectives Short interspersed elements B2 (SINE B2) are broadly distributed transposable elements in whole mouse genome. Evolutionally, SINE B2s share common ancestors with tRNAs. Among the various remarkable functions of recently discovered non-coding RNA functions, we discovered a new class of antisense non-coding RNAs (SINEUPs) that promote translation of partially overlapping sense coding mRNAs with no effects on RNA levels.. In order to develop synthetic SINEUPs to up-regulate therapeutically interesting genes, we have determined that SINEUPs function requires two essential domains; one is SINE B2 element, also called the Effector Domain (ED), and the other is overlapping antisense RNA sequence, which provide specificity and is called the Binding Domain (BD). We have produced functional SINE-UPs for to a PD associate gene, PARK7 (DJ-1), as well as other genes. This synthetic SINEUP specifically enhances translation level of PARK7 mRNAs in human neuronal cell lines. Through a novel high-throughput screening (HTS) system, we aim at further optimization of the ED and BD of SINEUPs to produce very effective SINEUPs against any possible mammalian protein.

Methods
We report here our HTS, which is based on high-resolution automated fluorescent imaging of CeligoS instrument. We screened with the HTS several BDs for a hepatic transcription factor alpha (Hnf4alpha), which is associated to maturity-onset diabetes of the young type 1.

Results
In addition, we validated that several SINEUPs targeting Hnf4-alpha are able to upregulate translation in mouse hepatoma cells and hepatocyte cells. We also validated that other EDs derived from natural SINE B2 sequences revealed target mRNA specific translation enhancement.

Conclusion
To conclude, synthetic SINEUPs are promising tools for gene/RNA therapy of haploinsufficiencies, and the HTS system is a powerful SINEUPs screening platform.

Disclosure of interest
None declared. Objectives Rare and undiagnosed disorders challenge patients, families, and clinicians. In 2008, NIH started an Undiagnosed Diseases Program (UDP), with the goals of providing answers to patients with mysterious conditions that eluded diagnosis and advancing medical knowledge about diseases. The UDP has expanded in the US, as the Undiagnosed Diseases Network, with 6 additional clinical sites, a coordinating center, 2 DNA sequencing cores, a model organisms screening center, a metabolomics core, and a biorepository. For further expansion, meetings were held in Rome and Budapest with clinician scientists from 7 nations.

Methods
The plan includes launching the UDNI (Australia, Canada, Hungary, Italy, Japan, Sweden, and the United States). The goals are to improve the level of diagnoses and care for such patients by common protocols, to facilitate research in disease etiology, and to create a collaborative research community. A comprehensive "-omics" approach would include exomic and genomic sequencing as well as metabolomics. The interim website is http://test.areasrl.com/udni/home.

Results
To date, several principles are being implemented: Engaging centers of excellence, fostering a collaborative research environment, establishing a cooperative governance structure, designing a common research protocol, providing a uniform patient experience, collecting data by recognized standards, protecting patient data, observing ethical, legal, and social guidelines, devising broad data sharing, stimulating dissemination of results, and ensuring a well-functioning network.  Objectives Several computational methods have been developed to predict whether amino acid substitutions result in disease. This type of analysis is included in the ACMG/AMP guidelines for pathogenicity classification of variants and is being used by the Clinical Genomics (ClinGen) resource. These methods are generally blind to the underlying disease mechanism. Little is known about how mechanism of disease affects the predictive ability of these algorithms for variants implicated in inherited diseases. We address this by focusing on two classes of genes that differ in their molecular mechanism of action. Activating/gain-offunction mutations in oncogenes and loss-of-function mutations in tumor-sppressor genes(TSG) are pathogenic in cancer development. Moreover, unlike TSG, oncogenes are recurrently mutated at several amino acid positions.

Methods
We obtained 5078 missense variants in 29 oncogenes and 50 TSG, classified based on their pattern of mutations in COSMIC(1), from the ClinVar database and annotated them with 20 computational algorithms. These variants had clinical assertions provided by the submitting laboratory. We analyzed variants classified as either pathogenic or benign in oncogenes (n=321) and TSG (n=832).

Results
We found less concordance among the algorithms assessed for pathogenic variant prediction in either class of genes. Also the set of algorithms that were concordant in predicting benign and pathogenic variants differed on whether the variant was an oncogene or TSG. The concordant (e.g. GERP++) algorithms are primarily based on evolutionary conservation. A combination of GERP++ and the functional prediction algorithm FATHMM is more likely to produce discordant results for oncogenes. This implies that curators choosing different sets of computational algorithm are likely to result in different inferences for the same variants. We are developing statistical approaches to identify algorithms that produces maximal separation of benign and pathogenic variants for oncogenes and TSGs and applying them in a larger set of variants in the list of 56 genes recommended for reporting for incidental findings differing in their disease mechanism. Conclusion We find evidence that disease mechanism needs to be taken into consideration when deciding on algorithms for predicting pathogenicity. Our findings may aid in further classification of variants of uncertain significance.

Objectives
The Baylor College of Medicine's Human Genome Sequencing Center and the Mayo Clinic's Center for Individualized Medicine are collaboratively working to sequence up to 10,000 patients from the Mayo Clinic Biobank. The objective of these efforts is to incorporate the results in patient electronic health records (EHRs) thus guiding clinical drug prescribing practices in terms of efficacy and avoidance of adverse events.

Methods
This study takes a prospective approach using a combination of reagents including a targeted panel of seventy-six pharmacogenomically relevant genes developed as part of the Pharmacogenomic Research Network (PGRN). Specific targets are based primarily on a combination of community feedback and clinical guidelines published by the PGRN's Clinical Pharmacogenetics Implementation Consortium (CPIC). The targets include both gene coding regions and SNP targets aimed at characterizing both known and novel variants while keeping the costs equal to or below microarray-based genotyping approaches.

Results
Preliminary data was generated using 500 samples used previously as part of the Mayo Clinic's eMERGE Network studies. Each institution developed both data generation and analysis pipelines geared toward identification of genomic variants and haplotypes influencing commonly prescribed drug efficacies and toxicities. Preliminary sequencing data quality was outstanding and demonstrated high variant correlation with the previous dataset. Improvements in haplotype calling and clinical decision support are ongoing. Moving forward, the Mayo Clinic's Center for the Science of Health Care Delivery will be tracking outcomes to confirm the value of this approach.

Conclusion
In conclusion, this study will provide a large cohort blueprint for implementation of pharmacogenomics in precision individualized health care.

Disclosure of interest
None declared.

Objectives
Targeting immune checkpoints has proven to be an effective strategy for the treatment of metastatic melanomas. However, less than half of patients respond to the immune checkpoint blockade. A complete understanding of molecular mechanisms underlying tumor response is lacking. In this study, we propose that the degree of melanoma cell "re-programming" may contribute to melanoma tumor resistance to immune therapy.

Methods
We employ RNA-sequencing (RNA-seq) and Reverse Phase Protein Array (RPPA) data from 68 early passage melanoma cell lines derived from tumor infiltrating lymphocyte harvests of 63 patients to identify biological processes and marker genes underlying the melanocyte "re-programming". We propose a scoring system of the process based and employ it to study effects of the re-programming on outcomes of the immune therapy using a transcriptomics dataset (Van Allen et all, 2015) from pretreatment metastatic melanoma tumor samples from patients treated with ipilimumab (anti-CTLA-4).

Results
Melanoma cells grouped into 3 major concordant clusters by both RNA-seq and RPPA analysis (Fig. 5). Examination of the genes underlying the clustering revealed profound differences in the expression of genes associated with melanocyte differentiation (including MITF) and with the Epithelial to Mesenchymal Transition (EMT) process. We determined the mean Z value for genes within each process, and designated the difference between the mean expressions as the "reprogramming score" (RPS). Using the same set of marker genes for melanoma tumor samples we significantly separated responders from non-responders of the immune therapy and revealed 2 groups of non-responding tumors. Each group had a different subset of highly expressed EMT-associated genes, and opposite expression of the differentiation-associated genes. Combining a subset of genes that are differentially expressed between responders and non-responders we markedly enhanced the prognostic value of the cytolytic score, a known prognostic feature. Conclusion The proposed scoring system of the melanocyte re-programming based on the RPS may hold prognostic value for immunotherapy treatments outcomes.

Disclosure of interest
None declared. Objectives Challenges in research, diagnosis and treatment of complex disease emerge from the poor alignment of the underlying biology of disease with a nosology defined by externally manifest signs and symptoms. Aggregate functional genomics data can enable the development of a data driven nosology in which disease characteristics, research models, diagnostic categories and drugs are more precisely aligned to specific, biologically based facets of disease. Methods GeneWeaver consists of a database and analysis tools for aggregation of heterogeneous functional genomics data across species, including curated pathways, ontology annotations, publication data, genetic mapping, transcriptome and proteome experiments, and other functional genomics data including user-submitted experimental results. Each is described with meta-content, enabling retrieval by disease related terms. Gene identifiers are harmonized to enable aggregation of data through homologous genes and gene products. To evaluate specificity of disease descriptors, we analyzed intersections among gene sets associated with disease-related terms. These gene sets were derived from studies of nine different organisms and consisted of genome-wide experiments, curated annotations to ontology terms and genes associated to disease-related terms through transitive association of genes, publications and MeSH terms.

Results
Analyses of term-to-term associations reveals that genes associated to co-occurring or difficult to discern diseases exhibit weak overlap across many different terms, especially those associated with psychiatric disorders which display extensive cross-disorder overlap. In contrast, more well-bounded disorders, such as degenerative ocular disorders, reveal strong and specific overlap and good matching of empirically derived data sets and annotations. By enumerating all intersecting associations of genes to disorders, we are simultaneously able to identify genes that differentiate among overlapping disorders, potentially defining the specific and unique aspects of these conditions for precise differentiation of disease.

Conclusion
The integration of heterogeneous functional genomics data provides insight into the latent biological basis underlying the organization of heterogeneous disease. Supported by NIH AA18776, jointly funded by NIAAA and NIDA.

Disclosure of interest
None declared. Objectives How to efficiently extract biomarkers for risk prediction and treatment selection from millions or dozens of millions of genomic variants raises a great challenge. Traditional paradigms for identifying variants of clinical validity are to test association of the variants. However, significantly associated genetic variants may or may not be efficient for diagnosis and prognosis of diseases. Alternative to association studies for finding genetic variants of predictive utility is to systematically search variants that contain sufficient information for phenotype prediction.

Methods
To achieve the goal, we introduce concepts of sufficient dimension reduction (SDR) which project the original high dimensional data to very low dimensional space while preserving all information on response phenotypes. We then formulate a clinically significant genetic variant discovery problem into the sparse SDR and optimal scoring problem and develop algorithms that can select significant genetic variants from high dimensional data. To speed up computation, we apply the alternating direction method of multipliers to solving the sparse optimal scoring problem which can easily be implemented in parallel.

Results
To illustrate its application, the proposed method is applied to a coronary artery disease (CAD) dataset from the Wellcome Trust Case Control Consortium (WTCCC) study, Rheumatoid Arthritis (RA) dataset from the GWAS of North American Rheumatoid Arthritis Consortium (NARAC) and the early-onset myocardial infarction (EOMI) exome sequence datasets which have European origin from the NHLBI's Exome Sequencing Project. To evaluate the performance of the SDR for disease risk prediction, we present Table 1 that lists AUC of our SDR and other 10 existing methods. Table 1 clearly demonstrated that our proposed SDR method has much larger AUC than other 10 existing methods.

Conclusion
We shift the paradigm of feature selection from P-value and risk score ranking to optimal genome-wide searching. The SDR-based optimal genome-wide searching methods substantially outperform other existing methods for disease risk prediction. Our results strongly demonstrate that the rich genetic variation information provides powerful resources for disease risk prediction.

Disclosure of interest
None declared.

Objectives
Next generation genomic and image technologies produce a deluge of DNA sequencing, transcriptomes, metabolic, image, physiological phenotypes with millions of features. Analysis of increasingly larger and more complex data gives scientists access to vast amounts of information that was previously unavailable, but also poses great methodological and computational challenges. This talk provides perspectives for paradigm changes in current public health data analysis.

Methods
We develop novel statistical methods for paradigm changes in big genomic, epigenomic and imaging data analysis from low dimensional data to high dimensional data analysis. We develop novel functional structural equations with integer programming as a new framework for inferring large-scale causal networks of genomicimages and detecting pleiotropic effects of genetic variants on imaging. In addition, we develop new causal machine learning methods for network classification and combine images and genomic data for disease risk prediction.

Results
The proposed method for large-scale genomic-imaging causal network analysis was applied to the MIND clinical imaging consortium's schizophrenia image-genetic study with 142 diffusion tensor images (DTI) with 538265 voxels and 14,412 genes in 64 schizophrenia patients and 78 controls. Each DTI were segmented into 41 regions. The causal image-genotype networks were constructed for all the individuals. In cases, the image network consisted of 41 nodes and 68 edges, and in controls, the image network consisted of 41 nodes and 65 edges. We identified 1,035 and 1,618 genes that were significantly connected to the image regions respectively. 27 genes in cases and 40 genes in controls were in the 108 schizophrenia associated genetic loci. The developed network classification algorithm was also applied to predict schizophrenia. Using cross validation, we can achieve 100% prediction accuracy in the training data and the average prediction accuracy, sensitivity and specificity in the test data were 95.1%, 96.2% and 93.9% respectively.

Conclusion
We shift the paradigm of big genomic and imaging data analysis from association studies to causal inference and provide powerful tools for unravelling causal chain of mechanisms of psychiatric disorders, delivering new therapeutic targets and biomarkers for precision medicine  In the wake of the development of new Next Generation Sequencing (NGS) instruments and methodologies, genetic research has become more prominent during the past several years. However, many laboratories and institutions still face significant issues in their modus operandi: Storage, processing, and sharing of NGS data and results. We propose a novel approach to overcome mentioned issues: Wikinome, a cloud based platform specifically designed and developed to deal with the issues typical bioinformatics laboratories are confronted with, allowing faster and more efficient ways to conduct NGS data analysis. Methods Wikinome allows its users to store, manipulate, analyze and share their data and results from anywhere, using desktop computers, laptops, or even mobile devices, without the need of maintaining a high powered computer in the lab. Once the NGS data are uploaded, it can be analyzed using various pipelines that can be planned and executed using any of Wikinome's clients. Utilizing a Service oriented Architecture (WCF), all steps of an analysis workflow are called individually to perform the underlying analysis process, such as readsmapping, reads-clustering, or performing a BLAST search. Accesscontrolled files in a Big Data Storage environment allow users to share data with collaborators at the ease of a button click, instead of physically or digitally moving data.

Results
We have successfully implemented a platform allowing all people and institutions that conduct genetic sequence analysis, to completely move their analysis procedures into the cloud, independent from the sequencing instruments that were used to produce the NGS data. Utilizing standard modules such as quality control, referencemapping, gene-detection, de-novo assembly, alignment, and BLAST, Wikinome not only allows users to define custom analysis workflows; users can even add services hosted inside their own labs, without the need of exposing them in the cloud. Instead of working with command-line based algorithms and tools, users are automatically notified upon finishing certain procedures of the currently running workflow, and have access to live updates. Users can also add their own custom analysis modules and share them with collaborators within the Wikinome network.

Conclusion
With Wikinome, we have successfully developed a solution to perform analysis on NGS data on a previously unthinkable scale with the potential to overcome many of the typical Big Data issues in the field of genetic research and analysis.

Disclosure of interest
None declared. Objectives Efforts to move high throughput sequencing into the clinic must confront many challenges including meeting clinical standards for cost, reproducibility, quality, ethical and privacy considerations. The Melbourne Genomics Health Alliance was formed from a diverse group of institutions with the aim of sharing the burden of these challenges through a common sequencing and bioinformatics platform. In this work, we present a shared, open source analysis pipeline that was developed to meet these needs.

Methods
To enable a single solution for many different diseases and laboratories, we employed the Bpipe pipeline platform which allows for analysis stages to be easily added, substituted, replaced or customized on a per-sample or per-disease basis. Bpipe also offers powerful Objectives This project aims the formulated algorithm will be implemented explicitly on lung cancer pathological images. Specifically, this project has two goals. First, it aims to apply the concept of deep neural networks to supervised learning in the classification of images, with the understanding that modifying existing machine learning methods to target specific image sets can optimize the precision and accuracy of the analysis. The algorithm that will be formulated will be able to sort a given set of data (in this case, images) into desired sets with given qualifications. Second, it aims to apply the concept of deep neural networks, supplemented by Bayesian networks to pattern analysis of lung cancer data sets. Performing Bayesian network procedures on given lung cancer data can help us determine parameter values that will characterize those data. In turn, those parameters can be used to infer whether or not new data can be classified with the given training data or otherwise. Methods First, we take tiles of size 512x512 from images published on the cancer genome atlas database (http://cancergenome.nih.gov). Several samples from those 512x512 will be segmented further into 32x32 subregions, which will be used as an example training dataset. We then incorporate the Sobel operator feature detection method, along with the standard RGB image histogram to serve as the main features for classification. These features will be extracted through the notion of deep neural networks. The algorithm will then return a classification of the subregions into either normal or abnormal, by virtue of a Bayesian classification scheme. Results 3,233 tiles of size 512x512 were gathered from two whole-slide lung cancer images. Samples from these tiles were segmented further into 32x32 subregions, which served as training data for the algorithm.
The main output will be an algorithm embedded in a web application wherein the user can just input newly acquired images, and the program can provide classify which 32x32 subregions depict cancer cells. A demonstration of the application can be shown during the presentation.

Conclusion
An executable program, whose input is a lung cancer image, will be segmented into 32x32 subregions, each of whose features will be extracted using deep neural networks and will undergo a Bayes' classification scheme, and determine whether the subregion is normal or abnormal, either because of a broken cell, a stained cell, or an actual cancer cell. Objectives The increasing amount of heterogeneous genomic datasets generated today necessitates a robust platform for efficient data management and analysis. To address this need, we developed a software for the Management, Analysis, and Visualization of sequence data (MAV-seq), capable of addressing the issues related to the exponential growth of genomic applications and their datasets of enormous size and diversity. Our software also integrates various genomic preprocessing pipelines with user-friendly graphical interface to enable biologist with no programming experience conduct complex data analyses.
Methods MAV-seq (Figure) is a desktop application developed to integrate bioinformatics methods, software engineering principles, human computer interaction guidelines and big data analytics. The graphical user interface (GUI) and back end development of MAV-seq is performed in Java and Python, and schemas for backend data storage are implemented in MySQL and MariaDB relational database management systems. MAV-seq allows direct data manipulation using GUI as well as data import and export in "csv" file formats. Results: We developed MAV-seq as an interactive, user friendly, cross platform, encrypted and multi-roles based system for the management of sample repertoires and automation of the data preprocessing of epigenomic and transcriptomic data. It supports users in performing downstream data analysis by integrating several analysis pipelines for diverse data sets including ATAC-seq, mRNA-seq, tRNA-seq, Chip-seq, WES, WGS. MAV-seq can be customized for increasingly large scaled and complex datasets of different types. Moreover, it can directly interact with multiple data clusters to locate, input and process genomics data by automatically generating and running multiple-sequential and parallel pipelines. Conclusion MAV-seq is a comprehensive data management and analyses platform that is newly designed, developed, tested, validated and deployed at The Jackson Laboratory for Genomic Medicine. With this platform, we aim to advance genome-wide big data management, standardization and automation, which will expedite the pace and improve the levels of efficiency in loading, handling, tracking, securing, sharing, processing, analyzing and visualizing data.  Objectives Genome structural variations (SV) have been well established to be associated with diseases and traits; however, SV analysis of human genomes has been severely limited to date by technical shortcomings. Traditionally, SVs have been detected by microarray (limited to imbalanced copy number variation (CNV) with a short dynamic range, low resolution, and relative readouts), nextgeneration sequencing (NGS) (primarily CNV, some balanced events but too short to span most repeats) and karyotyping and fluorescence in situ hybridization (FISH) (both are very low resolution).

Methods
Using a single-molecule genome analysis system, BioNano Genomics Irys® System, utilizing next-generation mapping (NGM) technology, it is now possible to comprehensively analyze whole genomes for SVs > 2 kilobase pairs (kbp), including balanced events in a costeffective and high-throughput manner. This technology allows for the comparison of family pedigrees and populations, which is needed to potentially uncover genomic structural causes of Mendelian and complex diseases.

Results
We demonstrate the robustness of NGM for genome-wide discovery of structural variation in the CEPH trio set from the 1000 Genomes Project where the individuals were sequenced and analyzed in-depth. We generated de novo assemblies that covered at least 96% of the hg38 reference assembly. Compared to tens of large SV events detected by NGS, we uncovered hundreds of insertions, deletions, and inversions greater than 5 kbp, a large portion of which was novel, and some are located in the regions likely leading to disruption of gene function or regulation. Based on the pedigree structure, we estimated that the Mendelian concordance rate was 96%. We have also begun analysis of a trio of Ashkenazi Jewish descent from the NIST GIAB project, where we have found hundreds of inversions, insertions, and deletions, including large deletions in the UGT2B17 gene (involved in graft versus host disease, osteopathic health, and testosterone and estradiol levels) in the mother and son.

Conclusion
We show that NGM is a robust and effective method for structural variation detection in the human genome. Systematic whole genome structural variation within disease population cohorts is needed, in additional to the conventional SNP analysis, to study the effects of a full spectrum of genomic variations in human disease and complex traits.

Disclosure of interest
None declared.

Methods
Seventeen genomes from indigenous populations from PM and NB were sequenced using Illumina Hi-Seq, thus unveiled the full spectrum of genetic architecture of the MI. Population genetic structure of these samples were assessed with PCA and ADMIXTURE. Inference of coalescent time and effective population size were performed using PSMC, and gene flow was estimated using TreeMix. Archaic genomes introgression was estimated using the D-stat and f-test. S* analysis was applied to identify the introgressed genome segments.

Results
The divergence between Negrito and Austronesian occurred~20K years ago, and were gradually replaced by the Austronesian expansion. Events of multiple gene flow into PM and NB was observed, in line with previous investigations. However no evidence of significantly higher gene flow from archaic genomes to MIs was observed, and that the archaic DNA segments found in MIs were different from those carried by the East Asia and Europeans.

Conclusion
Our analyses further strengthens the findings of the population structure of the indigenous people revealed by various earlier studies using SNP array, yet suggests that the history of these populations are far more complex than expected. The archaic genome introgression provided evidence of no significantly higher archaic genome component in our samples. This preliminary study complements the gaps of various speculations about archaic genomes introgression in the regions of SEA and Oceanic.

Disclosure of interest
None declared. Objectives Germline mutations in BRCA1 and BRCA2 confer high lifetime risk of breast and ovarian cancer but importantly these risks are not irreversible. Identification of asymptomatic carriers could significantly reduce the incidence of these diseases. As a first step toward population based BRCA gene screening, we are sequencing the entire coding region of 20 known and proposed HBOC genes in 4,000 cancer-free Australian women. Methods Cancer-free women were selected from the LifePool study (www.life pool.org) which is a cohort of women attending the Australian population, based mammographic screening program. All exons of the target genes were enriched using the Haloplex system (Agilent) and sequenced on a HiSeq2500 instrument (Illumina). The data were filtered for known pathogenic or novel loss of function mutations.

Results
To date, data from 1,997 women has identified 17 with actionable mutations in BRCA1 (4 mutations), BRCA2 (9 mutations) or PALB2 (4 mutations). All 17 women subsequently accepted an invitation to attend a Familial Cancer Centre and then proceeded to formal clinical genetic testing. In addition 4 women had pathogenic mutations in BRIP1.

Conclusion
Our unique pilot data directly demonstrates a population carrier frequency of~1% for pathogenic mutations in these recognized high risk breast and/or ovarian cancer genes and that such testing is well accepted by the screened population.

Disclosure of interest
None declared. Objectives In order to conduct comprehensive analysis of whole genome sequencing (WGS) or whole genome bisulfite sequencing (WGBS), unbiased, even coverage of the genome is required. To maximize time and cost efficiency, it is imperative to attain coverage from the lowest possible sequence read depth. Highly efficient conversion of DNA fragments into library molecules is especially imperative when DNA input quantity or quality is limited. To address these concerns, we have developed two novel library preparations which enable highly efficient DNA library preparation from low input while maintaining even genomic coverage.

Methods
The WGS method uniquely repairs damage on both the 3′ and 5′ termini to enhance ligation efficiency to DNA fragments. Combined with sequential ligation steps, this single tube method supports PCR-free sequencing from inputs as low as 10 ng circulating, cell-free DNA (cfDNA) or 50 ng physically sheared DNA. For WGBS, our library preparation is performed on denatured, bisulfite-converted fragments. This improves library recovery significantly compared to traditional library prep methods that ligate methylated adapters to double-stranded DNA prior to bisulfite conversion. Our adapter attachment to single-stranded DNA supports inputs from 100 pg to 10 ng Input quantities down to 10 pg can be used with PCR amplification.

Results
Using the WGS method, library conversion efficiency was~50% for physically sheared DNA and up to 90% for cfDNA. Human WGS using this method demonstrates high complexity with exceptional coverage of GC-rich promoter regions. At inputs as low as 1 ng human DNA, at 16X coverage, the genome was fully represented with consistent, uniform coverage. Libraries made with the WGBS method required less PCR amplification than other available kits and this improvement was further seen in the sequencing data, particularly at 1 ng input. Human WGBS demonstrated comprehensive coverage of CpG islands when 10 ng input was used at low depth of sequencing. This library preparation method enables single base resolution of methylation status throughout the genome, even from limiting DNA input quantities.

Conclusion
We have demonstrated the utility of increasing the efficiency of library preparation as a means of improving sequencing results obtained through both WGS and WGBS. This innovative technology enables sequencing of sample types that have been previously unusable due to input or quality limitations.  However, successful execution of such projects will require design of robust sample preparation (library) workflows that can work with a spectrum of DNA quality and quantities. This is especially true for the highly desirable PCR-Free libraries that are known to provide improved gene and genome representation compared to PCR amplified libraries. Here we discuss the use of multiple PCR-Free protocols for use on HiSeqX. Methods Previously we automated Illumina TruSeq PCR-Free protocol, which is recommended to use with 1 ug of good quality DNA to prepared size selected libraries. However, to broaden the scope of samples that can be used for preparing PCR-Free libraries, we evaluated two additional library construction methods 1. Swift Biosciences 2S library kit and 2. Kapa Biosystems, hyper prep kit. PCR-Free libraries were prepared using 200 ng -1 ug DNA of HGSC internal human control sample (HS1011) with these kits and sequenced on HiSeqX to generate 34-38X genome coverage data.

Results
Exome representation as measured by complete coverage of Online Mendelian Inheritance in Man (OMIM) genes at 20X read depth was lowest for the TruSeq PCR-Free libraries (2687 genes) when compared to the 2S libraries (2750 -3020 genes) and the Kapa hyper libraries (2800 genes). GC representation was better in PCR-free libraries when compared to the TruSeq Nano libraries. Kapa Hyper protocol was optimized on Beckman Coulter's Biomek FXP liquid handler using 500 ng DNA and can prepare 96 libraries in~6 hours. This protocol also works well with DNA of different integrities. Enhancements have also been made for precise quantification of PCR-Free libraries by qPCR and to eliminate unused adapter molecules in libraries that can impact sequencing.

Conclusion
Availability of such robust and automated protocols has positioned us to efficiently work with large sample sets to fully exploit the use of HiSeqX platforms for population level genomic studies and to drive its use in clinical setting.

Disclosure of interest
None declared.

Objectives
Advancement of next generation sequencing in clinical settings has required methods for rapid, robust delivery of high-quality sequencing data. Effective and timely diagnoses or prediction of risk of genetic diseases are important for medical intervention.

Methods
We have developed a 'lightning capture' process to deliver variant calls in 5-7 days after sample intake. This process includes: quick enrichment library preparation (5-6 hours), capture enrichment (about 8 hours), rapid sequencing (Illumina HiSeq2500) and data analysis via the HGSC-developed Mercury pipeline. The lightning capture protocol has been deployed in BMGL clinic lab for whole exome sequencing (WES) and recent carrier screening with a novel 500kb carrier mutation gene capture panel. Our WES design contains 3643 clinically relevant genes primarily from GeneTests and OMIM, and the carrier panel includes 168 complete genes that contain at least 850 known common genetic variants of clinical relevance. We also employ the genotyping with SNPTrace panel by Fluidigm in order to ensure reliable sample identification, and to test for sample crosscontamination.

Results
This method has been validated with~500 WES and more than 5000 carrier samples. WES samples are processed in single capture or 3-plex co-capture, while carrier samples are in a cost-effective 47plex cocapture format for hybridization followed by sequencing of 94 samples (2 capture pools) per HiSeq 2500 lane. High enrichment efficiency was observed (72-80% reads on target and buffer) and superior coverage metrics across the design with 11 Gb sequencing yield for WES and~400 Mb for Carrier samples. A detailed analysis of the carrier design performance using 140 de-identified samples found that known carrier mutations were correctly identified with high confidence (98.5%), including large/complex indel mutations. Conclusion Sample turnaround time for tests is often considered one of the most significant measures of performance for a clinical lab. The lightning capture process we developed enables data delivery in 5-7 days without sacrifice of data quality. This novel method may impact applications in prenatal, neonatal intensive care and other critical settings for clinical and research samples.

Disclosure of interest
None declared. Objectives Generate a high quality reference genome from a single individual to avoid limitations of the haploid mosaic human reference and explore the contribution of different data types to understanding the comprehensive clinical genome. Methods Illumina data from a variety of libraries (180 bp, 300 bp and 500 bp paired end data; 3kb, 6.5 kb and 8 kb mate-pair data), as well as Illumina Hi-C data, 20x PacBio RS long read data and BioNano optical mapping data were produced and assembled de novo. Structural variants that are difficult to characterize with exome sequencing or short sequence reads from small fragments were identified using two methods. We identified putative novel insertions in reads that did not map to the GRCh38 reference with calls supported by 6.5 kb mate-pair data, and confirmed in the de novo WGS assembly contigs and 3 kb mate-pair data. We identified tandem duplications with combined signatures of inverted 300 bp to 500 bp read pairs identifying the boundaries and larger read pairs confirming the size of the duplicated region.

Results
We report here the assembly of data from a single individual (HS1011). The data are available at NCBI under BioProject 203659. The released assembly is highly contiguous with a 394 kb Contig N50 and 148 Mb Scaffold N50 with full chromosome scaffolds. Data from the parents of HS1011 and long-read data allow us to phase variants within this genome. Putative novel insertions (78) and tandem duplications (70) were identified.

Conclusion
The assembly and underlying data reported here allow us to optimize methods to combine these data types and explore the utility of the different data types to identify structural variation and define which heterozygous variants are located on the same haplotype for haplotype-aware downstream analyses.

Disclosure of interest
None declared. Objectives Discoveries of chromosomal alterations ranging from single nucleotide variants (SNVs) to large structural variants (SVs), via nextgeneration sequencing (NGS) techniques, have drastically impacted the delineation of genomic architecture and disease mechanisms. However, in contrast to being able to identify SNVs efficiently and accurately, current short-read NGS platforms have been inefficient for discovery of complex chromosomal rearrangements. To detect chromosomal pathogenic SVs, we have developed a novel method, Pacific Biosystems large insert targeted capture-sequencing (PB-LITS). We further tested PB-LITS protocol for detection of clinical relevant complex gene structural mutations with a set of 6 breast cancer samples. Methods Genomic DNA was fragmented to 6kb and ligated with Illumina adaptors, followed by size-selection at 4.5kb-9kb range. Long range PCR was performed on size-selected inserts. Pre-Capture PCR products were hybridized with a set of NimbleGen SeqCap probes targeting 94 genes that represent a spectrum of diseases with low, and thus unsatisfactory, sequencing access by current short-read NGS methods. Captured products were processed by standard PacBio large insert library preparation procedure. The final product, a 6kb insert capture library with single molecule, real-time (SMRT) bell adaptors, was sequenced on PacBio RSII platform.

Results
Initial PB-LITS protocol has shown its value of discerning complex structural rearrangements with 1.5ug input DNA 1 . Further development of PB-LITS enabled successful construction of 6kb-insert capture library with minimal 150ng input, by optimizing adaptor ligation and long range PCR reaction. Sequencing with 2~3 SMRT cells of HapMap DNA libraries constructed by current protocol yielded 20x coverage of 93% of 14mb target size with an average insert size of 3.7kb-7.1kb. Sequencing and further analysis of the libraries constructed from 6 cases with strong family histories of breast cancer who previously tested negative for mutations in BRCA1 and BRCA2 are undergoing.

Conclusion
Optimized PB-LITS protocol provided a reliable research tool for studying complex chromosomal SVs. Development of library construction procedure of PB-LITS has laid solid foundation to employ the method in clinical settings where identification of pathogenic complex SVs with limited sample amount is challenging.

O58
Rhesus macaques exhibit more non-synonymous variation but greater impact of purifying selection than humans

Objectives
We generated whole genome sequence data for 133 rhesus macaques (Macaca mulatta), the primary nonhuman primate in biomedical research. Methods Using the intersection of GATK and SNPTools SNV calls, we identified 43 million high-quality SNVs, including >126,000 missense and >148,000 synonymous coding variants.

Results
Comparisons with equivalent whole genome data from the Human 1000 Genomes project shows that macaques have 2.5-fold higher levels of overall variation and 20% higher levels of nonsynonymous variation per individual. Comparing the ratio of nonsynonymous to synonymous variants between species shows a lower ratio of NS:Syn in macaques, indicating more effective purifying selection, which can be explained by higher effective population size. Looking more specifically at 740 genes from the SFARI autism genetic association database, the ratio of NS:Syn variants among the macaques is lower in the SFARI gene set than in the complete macaque gene set.

Conclusion
These data suggest that large effective size in macaques leads to higher levels of both total and nonsynonymous variation than humans, and that purifying selection in macaques is more efficient in restricting mildly deleterious mutations.

Disclosure of interest
None declared.

O59
Assessing RNA structure disruption induced by single-nucleotide variation Z. Ouyang 1 , J. Lin 1 , Y. Zhang Objectives It has been challenging to interpret noncoding variants in complex traits and human diseases. RiboSNitches, single-nucleotide variants (SNVs) that alter the structures of RNAs, have recently found in many human diseases. RNA structure change mediated by riboSNiches has emerged as a plausible mechanism of pathogenic consequences of mutations. Thus, it is desirable to automatically predict riboSNitches from millions of SNVs of the human genome. However, current computational methods based on in silico RNA-folding algorithms suffer from limited accuracy. We seek to develop a new method for improved riboSNitch detection.

Methods
We introduce a new measurement to quantify the structural difference between the wild-type and mutant RNAs in which the two sequences are differed by an SNV. The new measurement is based on assessing the consistency of RNA structure change of individual bases. Using this new measurement, our method automatically selects a region that maximizes the effect of RNA structure disruption induced by an SNV.

Results
We applied our method to analyze a genome-scale dataset of riboS-Nitches and non-riboSNitches determined from the parallel analysis of RNA structure experiments on a family trio of human lymphoblastoid cell lines. The dataset contains rigorously validated subsets of 11 "probed", 63 "validated", and 223 "symmetric" riboSNitches. We found that our method consistently outperforms other existing methods on these rigorously validated subsets of riboSNitches.

Conclusion
Our new method improves the accuracy of computational prediction of riboSNitches. It facilitates the prioritization of noncoding variants for interpreting personal genomes. It also holds the promise to identify disease-causing variants potentially through RNA structure disruption.

Disclosure of interest
None declared.

P1
A meta-analysis of genome-wide association studies of mitochondrial dna copy number A. Moore 1 , Z. Objectives: Variation in mitochondrial DNA (mtDNA) copy number (CN) has been shown to be related to the risk of several cancers in prospective studies. The inter-individual variability of mtDNA CN is thought to be partially heritable; however, no genome-wide association study (GWAS) of the nuclear genome has yet been performed. Methods: We conducted a meta-analysis of GWAS of peripheral blood mtDNA CN using data from participants of European ancestry from nested case-control studies of prostate cancer and non-Hodgkin lymphoma in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial (n=1664). MtDNA CN was natural log-transformed and linear regression was used to evaluate the association, assuming an additive genetic model and adjusting for age at mtDNA blood draw, ancestry, and sex. The three GWAS were combined in a fixed-effects meta-analysis. Results: A quantile-quantile plot of the association results revealed some enrichment for SNPs with small p-values, but no evidence of genomic inflation (λ=1.007). Six loci, defined as +/− 1 Megabase, reached genome-wide significance (p < 5X10 −8 ), but all appeared to be singletons, indicating that they are likely to be false positives. Ten Single Nucleotide Polymorphisms (SNPs) in an intronic region of the long-range sonic Hedgehog signaling gene, DISP1, were found suggestively associated (p < 5X10 −5 )with mtDNA CN, with consistency in the direction of associations among all three GWAS. Conclusion: Preliminary findings from this meta-analysis suggest that there may be common genetic variants of the nuclear genome associated with mtDNA CN. We are currently augmenting our meta-analysis by including additional GWAS of nested case-control studies in PLCO and the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. We expect that the added statistical power will yield novel loci for mtDNA CN and provide new insight into the regulation of mtDNA CN.
Competing interests None declared.

P2
Missense polymorphic genetic combinations underlying down syndrome susceptibility E. S. Chen Biochemistry, National University of Singapore, Singapore, Singapore Human Genomics 2016, 10(Suppl 1):P2 Objectives: Single nucleotide polymorphisms (SNPs) drawn much attention as prospective biomolecular markers for human health management and disease therapies. Moreover SNPs have been surmised to constitute unique genetic makeup characteristic to each human individual, which can be utilized to cater therapeutic approaches to personalized medical care. Down syndrome (DS) or trisomy 21 is the most frequently occurring birth-related defects affecting live-born children. Molecular mechanisms that regulate and/or result in the formation of trisomy 21 in DS mothers, remain hitherto unknown. We posit a genetic basis for disposition of DS occurrence. We therefore performed bioinformatics studies of published nonsynonymous SNPs in conjunction with structural information of the proteins encoded by DS risk genes in the attempt to identify novel governing principles of DS risk. Methods: We surveyed all SNPs in the published literature focusing on missense mutations, and superimpose on bioinformatic reconstruction of secondary structural motifs of proteins encoded by DS genes Results: In our survey, we observed that even the most penetrant SNP implicated in DS is not completely associated with the disease. On the other hand, a combination of co-occurrence of SNPs is important, suggesting a synthetic cooperation between missense mutations to underlie occurrence of DS phenotype. Superimposing documented SNPs from several public databases showed a preferential localization of these SNPs with specific structural motifs within the proteins. Interesting, we noticed several closely situated SNPs that have not been reported to be associated with DS risk within regulators of the one carbon folate metabolism that included reduced folate carrier 1 (RFC1) and methionine synthase. These may represent novel SNPs that can be assessed experimentally in a targeted manner in future population studies. Conclusion: Taken together, our analyses showed that SNPs that result in change of protein sequences act synergistically to impact DS phenotype and suggest that SNP combinations to be a more reliable criteria than single SNPs for ascertaining DS risk, at least in the case of missense SNPs. Our study also identified probable secondary structural motifs implicated in DS risk-associating factors. These results will form the basis for future experiments that may hold potential for translation into personalized diagnosis or therapeutic management of DS.
Competing interests None declared. where transcriptional profiles in peripheral blood mononuclear cells (PBMC) from 42 healthy individuals, 59 CD patients, and 26 UC patients were assessed. We applied a newly proposed gene selection method, based on statistical and machine-learning principles, which finally delivered a set of models which best predicted the disease class. These models were inserted in a network where the biomarkers were placed in specific positions according to their relevance in discriminating between the diseases. Results: We found that a set of models, each containing only two RNA's from the PBMC, were sufficient to discriminate CD from UC patients and normal individuals. These RNA's were organized in networks where the gene in first position could well classify when placed in a model with any of those in the corresponding second position. A summary of these networks is as follows. Conclusion: Our statistical method is a new powerful tool that gives (1) the dimension of the statistical model, (2) the network organization of the selected genomic biomarkers, (3) a set of interchangeable models giving the same information. Moreover, all the RNA's in position 1 of the selected networks are known to have a clinical significance in Inflammatory Bowel Diseases. Amyloidosis is a well-known complication of CD and UC (Amyloid beta A4 precursor protein). Chemotaxis and neutrophil activation are fundamental pathways in the pathogenesis of IBD (Chemokine C-X-C motif ligand 5). RAB31 enhances FcγR-mediated phagocytosis through PI3K/Akt signaling in macrophages and plays a role in the maturation of phagosomes. Some clinical evidence links the menstrual cycle to the IBD activity (Progesterone receptor membrane component 1).
Objectives: Single nucleotide polymorphisms (SNPs) have been reported in different autistic populations. Here we present the first association study investigating SNPs of some genes; serotonin receptor (HTR2A IVS2A>G rs7997012; HTR2C 68G>C rs6318), serotonin transporter (SLC6A4 rs3813034), ankyrin repeat and kinase domain containing 1(ANKK1 rs1800497), methylenetetrahydrofolate reductase (MTHFR rs1891394), and BDNF rs6265 in Saudi autistic children. Epidemiologic, clinical and psychometric aspects were used to examine the possible risk factors of autism. Methods: We used TaqMan SNP genotyping to examine 68 Saudi children (48 Males and 20 females) diagnosed with autism according to DSM-IV criteria & ICD-10 criteria, including deficits in reciprocal social interaction, impaired verbal, and non-verbal communication as well as restricted, repetitive, and stereotyped patterns of behaviors. Healthy controls (n= 78) with no history of mental illnesses, behavioral disorders or substance abuse were used. The severity of behavioral symptoms in cases was assessed at admission using the Childhood Autism Rating Scale (CARS). Hardy-Weinberg equilibria of the genetic variants were assessed using online software (http:// www.oege.org/software/hwe-mr-calc.shtml). Chi-square tests were used to compare sociodemographic and clinical characteristics. Odds ratios and confidence intervals were calculated. Results: Overall, our data provide strong evidence of associations between these two SNPs and risk of autism in this population. Compared to healthy subjects, children with autism showed significant overexpression of the mutant alleles in the SNPs rs7997012, rs6318, rs3813034, rs1800497, and rs1891394, but not in the rs6265 SNP. Data on linkages or associations between these genetic loci and the disease vary among different ethnicities. Conclusion: Our findings presented associations between autism and some genetic variants under investigation, and showed that the potential influence of just one copy of the mutant alleles in the Saudi patients. Replicating our findings in other ethnic population may support our data before making any firm generalizations. Ongoing analyses of genetic variants associated with autism are being extended using next-generation sequencing and some fruitful data are going to be published.  Objectives: The majority of variants associated with common disease reside in non-coding sequence. Efforts to understand complex disease risk thus focus heavily on regulatory variation. How to seek biologically relevant sequences in which variation may reside and how to make in vivo predictions of the impact and function of regulatory variation remains a major challenge. We recently demonstrated how GWAS results can be informed by enhancer analyses in homogenous, phenotype-appropriate cell populations. Further, such enhanced datasets make feasible the prediction of functional variants. Presently, we are leveraging our past experiences to generate enhancer catalogues using homogenous populations of dopaminergic (DA) neurons better to understand the role of regulatory variation in Parkinson Disease (PD) and related disorders.

Methods:
We assayed open chromatin regions using ATAC-seq, producing multiple enhancer catalogues. Each catalogue is generated from 50,000 FAC-sorted DA neurons from either the forebrain (n=3 libraries) or midbrain (n=3 libraries) of E15.5 transgenic mice. Each ATAC-seq library is of high quality, yields over 30 million reads sequenced, with over 28 million reads mapping, and following filtering of reads, MACS2 calls~50,000 peaks, indicating intervals of open chromatin. Results: Our preliminary analyses indicate that peaks from all libraries show evidence of functional sequence constraint (PhastCons scores>0.3) and significant enrichment for processes and functions appropriate to neuronal function/dysfunction by GO/GREAT. The high quality of these open chromatin signatures also facilitate development of a computational classifier (regulatory vocabulary) of DA neurons. Consequently, we have begun to gain further insight into the transcription factors active in DA neurons and the nature of variation that might influence the function of identified DA enhancers. Conclusion: We are currently validating the DA neuron enhancer catalogues in vivo and are evaluating the shared and unique content of the catalogues and their pertinence to disease. Additionally, we have generated single cell and bulk RNA-seq from these isolated populations to corroborate and inform our chromatin-based findings. With this data in hand, we are able to assay the impact of PD and related movement disorders' GWAS-implicated variation on DA neuron function and disease pathogenesis. Objectives: To identify and characterize genetic modifiers capable of altering the retinal dysplasia observed in Nr2e3 rd7 mutants, a model for human Enhanced S-Cone Syndrome (ESCS). Methods: Nr2e3 rd7 mice were chemically mutagenized, and mated to generate a G3 population. The G3 mice were screened by indirect ophthalmoscope to establish lines bearing genetic modifiers that altered the pan retinal fundus spotting phenotype, characteristic of homozygous Nr2e3 rd7 mice. Quantitative trait locus analysis combined with high-throughput sequencing of an exome capture libraries was used to identify the molecular basis of modifiers of the retinal dysplasia in Nr2e3 rd7 mutants. Apart from fundus imaging, longitudinal histological studies were carried out to characterize the progression of altered retinal phenotypes. Finally, immunoblotting and marker analyses were performed to reveal the defects that underlie the rd7-retinopathy and how the defects were affected by the modifier(s). Results: Seven heritable modifier mouse lines with an altered retinal phenotype have been established so far. Among them three potential genetic modifiers have been identified, which directly or indirectly are associated with growth and development of neuroretinal cells. For example, the Tvrm272 line bears a nonsense mutation of the Rarb gene, which leads to a vitreal dysplastic phenotype that is more severe in the presence of the Nr2e3 rd7 mutation. While a reduced retinal spotting phenotype and suppression of formation of rosette-like structures associated with the rd7 retinopathy in the Tvrm222 line is due to a missense mutation in the Frmd4b gene. The modifying effect of the Frmd4b Tvrm222 allele is achieved through its effect on cell-cell junctions, revealed by immunoblotting and marker analysis. Conclusion: As an animal model of ESCS, retinal dysplasia in Nr2e3 rd7 mouse can be phenotypically altered by multiple genetic modifiers via different pathways. The modifying effects on rd7-associated retinopathies by these particular genetic modifiers, to our knowledge, are the first to be described. They provide novel insights into the pathogenesis of retinal dysplasia as well as degeneration in Nr2e3 rd7associated disease, and may become potential interfering targets for clinical applications against ESCS and related retinopathies.
Objectives: Targeted customized sequencing of genes implicated in the Autosomal recessive polycystic kidney disease (ARPKD) phenotype to identify candidate variants using next-generation sequencing by Ion torrent PGM. Methods: Eighteen unrelated ARPKD probands and healthy human adult control samples were recruited for genetic screening of ARPKD at a referral hospital from northern region of Saudi Arabia. Probands had survived the neonatal period and had age range in between 2 months to 13 years. Ion-Torrent PGM sequencing: We have customized primers and a target enrichment kit for targeting of the ARPKD candidate gene (PKHD1), and also included the PKD1 and PKD2 genes that may mimic the phenotype of the ARPKD. The NGS protocol involves three steps (1) Library preparation (2) Template preparation, finally sequencing was performed on PGM using Ion PGM 200 sequencing kit. Mapping assembly and variants discovery from NGS data: For each resulted deleterious variants identified by NGS were also confirmed by Capillary sequencing. Results: We identified five potential pathogenic missense variants in PKHD1 gene in 12 ARPKD Saudi patients. One missense variant was novel and other four had been reported in other ethnic groups but not in Saudis. The rest of the patient's samples have few variants in PKD1 and PKD2 genes that were not in damage but two causative variants observed. One missense homozygous variant c.4870C>T, p.(Arg1624Trp) was common in eight patients in PKHD1 gene derived from a male proband. Our results showed that the deleterious missense variant detected in PKHD1 gene was pathological significant or damaged were identified by computational predictions Sorting Intolerant From Tolerant (SIFT) and Polymorphism Phenotyping (PolyPhen2). Taken together, this strategy significantly lowers the cost and time for simultaneous targeted genes sequence analysis, and facilitating routine genetic diagnostics of ARPKD. Conclusion: Overall, the NGS TargetSeq exome sequencing may prove to be advantageous in the early diagnosis in patients with ARPKD disease.
Objectives: Neuronal cells are not homogeneously distributed and subtypes are intermingled with each other as well as with nonneuronal cells such as glia and blood vessel cells. When attempting to digitally profile the expression of a specific type of neuron, retrieving the RNA only of that cell type therefore poses a considerable challenge. Our aim was to isolate RNA specifically from Purkinje neurons in different parts of the cell body: soma (in different subcellular compartments, cytoplasm and rough endoplasmic reticulum) and dendrites. Methods: In previous work, we used a technology called translating ribosome affinity purification (TRAP) to isolate the ribosomeassociated transcriptomethe translatome. We modified it to target any cell type that can be specifically infected by a modified adeno-associated virus, and applied it to Purkinje cells (PCs) in the rat cerebellum. We obtained quantitative expression data in singlebase-pair resolution by profiling the ribosome-associated, isolated RNA using the nanoCAGE protocol. Results: Subsequent data analysis revealed the landscape of ribosome-associated RNA of PCs in different subcellular compartments: cytoplasm and rough endoplasmic reticulum in the soma. We published these results in [1]. Building on this work, we have now successfully retrieved RNA from dendrites in the same model system with replicated libraries, and thus obtained a deep sequencing using a newly developed protocol employing unique molecular identifiers (UMI) for a more precise measurement of expression. Conclusion: In neurons, protein translation occurs not only in the soma but also distally in dendrites near or within the dendritic spines. This distal translation is thought to be regulated in response to external stimuli including long-term depression and memory formation. We have applied TRAP to Purkinje dendrites and sequenced the isolated RNA with an improved nanoCAGE protocol including a tagmentation step, to address the increased difficulty of sequencing from dendrites, which contain even less RNA than Purkinje cell soma. Objectives: Genomes are products of natural processes. Hence all genomes contain functional and nonfunctional parts. Here, I present a functional classification of genomic elements and estimate the functional fraction within the human genome.

Methods:
The classification into different categories of functionality were based on the concept of selected-effect function. Intraspecific and interspecific genomic comparisons and standard evolutionary methodology were used to infer the functional fraction within the human genome.
Results: According to their selected-effect function, the genome is divided into functional and rubbish DNA. Functional DNA is further subdivided into literal and indifferent DNA. In literal DNA, the order of nucleotides is under selection; in indifferent DNA, only the presence or absence of the sequence is under selection. Rubbish DNA is further subdivided into junk and garbage DNA. Junk DNA neither contributes to nor detracts from the fitness and, hence, evolves under selective neutrality. Garbage DNA, on the other hand, decreases the fitness of its carriers; it exists in the genome because natural selection is neither omnipotent nor instantaneous. Each of these four functional categories can be transcribed and translated, transcribed but not translated, or not transcribed. The affiliation to a particular functional category may change during evolution: Functional DNA may become junk DNA, junk DNA may become garbage DNA, and so on; however, in the absence of prophetic powers determining the functionality or nonfunctionality of a genomic sequence must be based on its present status rather than on its potential to change in the future. Changes in functional affiliation are categorized into pseudogenes, Lazarus DNA, zombie DNA, and Jekyll-to-Hyde DNA. Intraspecific and interspecific genomic comparisons indicate that the functional fraction in the human genome ranges from 8% to 15%. Conclusion: A common misconception exists according to which evolutionary processes can produce a genome that is wholly functional. Actually, evolution can only produce such a genome if and only if the effective population size is infinite, the deleterious effects of increasing genome size by even one nucleotide are considerable, and the generation time is short. Not even in the commonest of bacterial species are these conditions met. In species with small effective population sizes and long generation time, such as humans, a genome that is~100% functional is contrary to reason.  Objectives: Here we present a new method for the identification of recurrent genomic entities that play a causative role in the onset of disease. Our approach is particularly amenable for the analyses highthroughput sequencing data. Existing approaches often follow a bottom-up approach where taxonomic determination necessarily takes place before associations to disease can be determined; naturally failing to establish the causality of novel pathogens not present in reference databases. Methods: To overcome this intrinsic limitation, we have developed a species-agnostic top-bottom approach that clusters sequences and identifies co-occurrence in multiple patients, associates recurrent sequences to disease and, finally, determines the taxonomic content where existing knowledge permits. Results: We analysed 686 sequencing libraries from 252 cancer specimens and 56 controls. Recurrent sequences were statistically associated to biological, methodological and technical features to identify novel pathogens and contaminants stemming from laboratory reagents.

Conclusion:
We provide examples of identified inhabitants of the healthy tissue flora, known experimental contaminants and uncharacterised sequences that co-occur with high statistical significance with disease. The latter represent a category that can only be addressed by a species-independent approach. Thus, our method helps to chart the unknown sequence-space where novel pathogens can be identified.

P19
Whole exome sequencing of dysplastic leukoplakia tissue indicates sequential accumulation of somatic mutations from oral precancer to cancer D. Objectives: Oral leukoplakia (OL) is the most common precancerous lesion in the oral cavity. The percentage of individuals with dysplastic OL in whom there is malignant transformation to oral squamous cell carcinoma (OSCC) is high, up to 36%. Germline and somatic copy number variations in mitochondrial DNA of OL patients have earlier been noted. We sought to test the hypothesis that about 36% of patients with the pre-cancerous lesion (OL) will possess somatic mutations in genes that are recurrently mutated in OSCC. Methods: Whole exome sequencing of DNA isolated from the affected oral tissue and from peripheral blood of twelve OL patients with dysplasia, was used to profile the landscape of autosomal somatic recurrent mutations in OL and to investigate whether mutations in the genes that drive OSCC are present in OL patients or whether the mutational landscapes of OL and OSCC are largely disjoint. Results: We have detected mutations in some genes that drive both oral leukoplakia and oral cancer. TGFBR2 is recurrently mutated in OL as well as in head and neck squamous cell carcinoma (HNSCC). Some significantly mutated genes in OSCC or HNSCC, viz., FAT1, NOTCH1 and CDKN2A are also found to be mutated in OL patients. Further, we have identified that MAPK signalling and oxidative phosphorylation (OXPHOS) pathways are significantly altered in OL patients. Conclusion: We have found that the proportion of OL patients with epithelial dysplasia among whom mutations were found in the set of genes that is also recurrently mutated in OSCC/HNSCC, closely corresponds to the fraction (~36%) of patients with dysplastic leukoplakia who develop oral cancer. The leukoplakia patients recruited in this study were free of malignancy in the oral cavity; our results are, therefore, not influenced by field cancerization.
Objectives: BRCA2-induced breast cancers share a predominant histologic and molecular phenotype (ER+, luminal B) that distinguishes them from most sporadic breast cancers and breast cancers arising in other inherited disorders. This suggests that breast cancers arising in BRCA2-mutation carriers have essential shared properties that drive carcinogenesis and can be targeted for intervention. To investigate this observation, we performed a cell biological screen in nontransformed breast epithelial cells for phenotypes specific to BRCA2 loss-of-function. Methods: Non-transformed breast epithelial cells were treated with siRNAs targeting hereditary breast cancer genes. Growth curves were obtained in complete growth media and growth factor-withdrawal medias. Whole genome sequencing and transcriptomics were performed. Functional cell biological assays including treatment with recombinant cytokines and inhibitors were performed. Results: Despite the role of BRCA2 in homologous recombinationmediated DNA repair, no recurrent de novo mutations were recovered. Instead, we discovered a novel pathway whereby BRCA2 depletion induces strong, persistent transcriptional activation of the chemokines on chromosome 4q13 (CXCL1, CXCL3, CXCL5, CXCL8). Surprisingly, these chemokines were sufficient to stimulate EGFindependent growth of non-transformed breast cells. Furthermore, inhibitors of the receptors of the chemokines impaired cell proliferation after BRCA2 depletion. Conclusion: Altogether, these findings indicate that transcriptional activation of the 4q13 chemokine locus induces an early cellautonomous autocrine signaling pathway in BRCA2-mediated carcinogenesis that could be exploited to prevent cancer onset.  Objectives: RNA sequencing (RNA-seq) is a powerful tool used for the interrogation of transcripts that enables the analysis of gene expression and the identification of nucleotide or structural variations. RNA-seq, however, can be cost prohibitive due to the size and complexity of most transcriptomes, which require deep sequencing coverage to achieve the necessary sensitivity for a reliable analysis. By combining targeted enrichment strategies with next-generation sequencing (NGS), a subset of transcript regions or sequences can be enriched and analyzed with the resolution required for both research and clinical applications. Here, we applied a novel RNA enrichment strategy, RNA DIRECT, to the capture of targets commonly associated with solid tumors. Methods: RNA DIRECT target enrichment utilizes cDNA and probebased hybridization to capture only desired cDNA sequences with removal of off-target regions via enzymatic digestion. Targeted sequences are then ligated to NGS platform specific adaptors and amplified by PCR. Results: RNA converted to cDNA was used for targeted enrichment with RNA DIRECT. Analysis of sequenced reads showed at least 97% alignment to the transcriptome with greater than 90% aligning to targeted regions. We also report the identification and detection of variants and gene fusions associated with solid tumors with high specificity and sensitivity. Conclusion: The RNA DIRECT strategy provides a robust and cost effective method for the enrichment of targeted transcript sequences for the identification and detection of known or novel variants and gene fusions. Objectives: Neuroblastomas are the most common of all malignancies in infants and the most common extracranial malignancy of childhood. With 650 new cases each year it accounts for over 15% of childhood cancer mortality. This neuroectodermally derived malignancy is most often found in the adrenal glands but can be found throughout the body in sympathetic ganglia. Though a small number of cases are familial (1-2%) with known genetic causes, most cases are sporadic with little known about what causes them or what causes the diverse outcomes of this disease. Methods: The current study used transcriptome sequencing to locate possible genetic mutations from a small cohort of neuroblastoma samples. The mutations were used to construct a phylogenetic tree that demonstrated the tumor progression and predicted the outcome. Results: Using this method a handful of associated mutations have been found, but few effect disease outcome. In this this study we used next generation RNA sequencing to fully sequence 249 neuroblastoma samples. Using these samples and focusing on indel mutations we located 1247 mutated genes that affect the favorable or unfavorable outcome of the disease. Due to the large number of mutations, online databases were used to identify genes associated with neuroblastomas. Comparing these genes to our sample we found a subset of genes that when mutated affected the survival rate of patients. Conclusion: This study suggests the importance of a few genes that drive the progression of neuroblastomas and determine the clinical outcomes.
Competing interests None declared. Objectives: Was to determine the regulation of fusion gene TMPRSS2-ERG by SFRP1 protein through negative regulation of AR Methods Cell culture. LNCaP, VCaP and PC3 cell lines from ATCC, were grown in RPMI 1640 PrSC cell line was grown in Stromal Cell Basal medium at the same conditions mentioned above. RWPE-1 cell line, was cultured in medium. For hormonal treatment, RPMI without phenol red was used it, supplemented with Charcoal Stripped serum 5%. Viability assay. Cells were plated in 96-well plates (1-2 x 10 4 per well). 48 hours after treatment, 10mL of MTT reagent was added per well and incubated 2 hours at 37°C and 5% CO 2. Next, medium was removed and 100mL of DMSO was added to solubilize formazan crystals. The absorbance it was readed at 575 nm wavelength. qRT-PCR. Cells were plated in 24 well plates (1 x 10 5 per well, except VCaP 2 x 10 5 ). RNA extraction it was realized with RNAeasy QUIAGEN kit according to the manufacturer's instructions. cDNA it was obtained retrotranscription assay, it was used Revert Aid Synthesis Kit according to the manufacturer's instructions. To real time PCR assay, the following taqman expression probes from Life Technologies company were used for avery target gene : GAPDH , KLK3 , AR , TMPRSS2 , ERG , TMPRSS2-ERG , SFRP1, FZD4, Wnt1, Wnt3a and LEF1. Results: We demonstrate that TMPRSS2-ERG is deregulated by SFRP1 protein through negative regulation of androgen receptor. Furthermore, our results indicates that androgen receptor (AR), is indirectly regulated by SFRP1 in the nucleus. We propose that the effect on fusion gene, down regulates the WNT pathway, and decreases the aggressive characteristics of the cell lines CaP. A negative effect on the TMPRSS2-ERG fusion gene by SFRP1, which was reflected in a decrease of neoplasic cell characteristics in LNCaP and VCAP PCa cells. Conclusion: TMPRSS2-ERG fusion gene is deregulated by SFRP1 protein through negative regulation of androgen receptor. Androgen receptor (AR), is indirectly regulated by SFRP1 in the nucleus. The effect on fusion gene, down regulates the WNT pathway, and decreases the aggressive characteristics of the cell lines CaP. A negative effect on the TMPRSS2-ERG fusion gene by SFRP1, which was reflected in a decrease of neoplasic cell characteristics in LNCaP and VCAP PCa cells. Objectives: Aggressive and potentially life-threatening prostate cancer often requires radical treatment. The many side effects that are associated with such treatments underscore the importance of accurate differentiation between these aggressive tumors and indolent prostate cancer in order to reduce overtreatment. Thus, we focus on the discovery of prognostic signatures based on changes in DNA methylation, stratifying by disease aggressiveness. Methods: Whole-genome bisulfite sequencing (WGBS) is costprohibitive for analyzing large numbers of human cancer specimens. Further, in order to detect subtle methylation differences between cancer samples and in samples with low tumor purity, higher sensitivity is achieved through a greater read depth, further increasing sequencing costs. Therefore, we utilize a targeted bisulfite sequencing method for the comprehensive analysis of genomic regions relevant to cancer, comprising 84 megabases (~3% of the human genome), covering 3.7 million CpGs, including most RefSeq and GENCODE gene promoters, all known cancer genes, CpG islands and their shores. Up to 100-fold read depth can be achieved on average by pooling four human prostate samples on one Illumina HiSeq4000 lane. Results: Of the differentially methylated regions (DMRs) we detected, the majority is hypermethylated in the aggressive versus the indolent prostate tumors. Most DMRs overlap a CpG island and are predominantly found in or close to gene promoters, as well as the promoter regions of long non-coding RNAs, and to a lesser extent within gene bodies or intergenic. Often, we find strong hypermethylation of the up-and downstream CpG islands surrounding the transcription start site (TSS), while the TSS itself stays unmethylated. Furthermore,~70% of the hypermethylated DMRs overlap regions reported to be a bivalent promoter in various cell types from the ENCODE project. The DMRs that can be associated with RefSeq genes are enriched for transcription factors, and more than half of those contain a homeodomain, such as different members of the HOX, SOX and FOX gene families. Conclusion: The overarching theme for DMRs called in this set of prostate cancers using a targeted deep Methylation-Sequencing approach is hypermethylation of regions within bivalent CpG islands, presenting a prognostic methylation signature that warrants further investigation.
Objectives: To know the frequency of the TPMT deficient alleles in children with acute lymphoblastic leukemia and healthy subjects from two Mexican populations Methods: We included 813 unrelated subjects, 392 were children with ALL and 421 were healthy subjects. Genotyping of the rs1800462, rs1800460 and rs1142345 SNPs was performed by TaqMan assays. To assess the differences of the genotype and allele frequencies among groups we used the Chi-square test. Written informed consent was obtained from both ALL children's parents and healthy participants. Results: The mutant TPMT alleles were carried by 5% of the 1636 chromosomes analyzed. Overall ALL cases, 10.2% of the subjects were heterozygote for one of the tree variants and only 0.2% were homozygote to the mutant allele TPMT*3A. We did not find statistically significant differences between Mestizo and Mayan ALL or controls groups; however, 7.8 % of the ALL Mayan bore one TPMT mutant allele. Moreover, 2.5% of the Maya healthy subjects were homozygote to the null phenotype (TPMT*3A/TPMT*3A). Conclusion: This study is the largest analysis of the TPMT mutant alleles performed in ALL Mexican pediatric patients [1]. Because ALL is the leading cause of childhood cancer in Mexico [2] and homozygotes TPMT deficient alleles subjects have high risk to develop severe and potentially fatal hematopoietic toxicity after treatment with standard doses of thiopurines [3]; TPMT alleles genotyping should be performed in Mexican ALL patients. Furthermore, largescale genotype and phenotype correlation studies are needed to assess the contribution of this variants in other Mexican-Amerindian populations.
Objectives: Alström syndrome (AS) is a progressive multi-systemic disorder caused by recessive mutations in the ciliary protein ALMS1. Amongst patients with AS, we observe variability in onset and/or severity of disease phenotypes including hearing and vision loss, obesity, hyperinsulinemia, hepatosteatitis, and cardiomyopathy, likely due to the presence of modifier genes. Like in patients, disease phenotypes in murine models of AS can be modified by the genetic background. The goal of the study was to map genetic modifier loci using an AS mouse model. Methods: A genetrap in intron 13 of the mouse Alms1 gene was placed onto the C57BL/EiJ and BALB/cJ inbred background strains, respectively. To genetically dissect modifier loci of AS, we performed a phenotypic screen of 135 Alms1Gt/Gt backcross progeny from two backcrosses: ((C57BL6/Ei X Balb/cJ)F1-Alms1+/Gt X C57BL6/Ei-Alms1+/Gt) and (C57BL6/Ei X Balb/cJ)F1-Alms1+/Gt X Balb/cJ/Ei-Alms1+/Gt). DNA of the backcross progeny was typed using evenly spaced microsatellite markers throughout the genome and quantitative trait locus (QTL) analysis was performed. Recombinational fine mapping and characterization of subcongenic lines was used to refine a retinal degeneration QTL on Chr. 2. Results: QTL for body weight, plasma insulin and triglyceride levels, alanine aminotransferase levels, hepatic steatosis, hepatic fibrosis, and retinal degeneration were mapped to regions on five chromosomes. The location of a major modifier locus on Chr. 2 in which the B6 allele protects Alms1 Gt/Gt retinas from rapid photoreceptor degeneration was refined to a 12 Mb region. A candidate mutation in the glutamylase TTLL9 was identified and is associated with reduced glutamylation of tubulin in Balb/cJ-Alms1 Gt/Gt retinas. Conclusion: Elucidation of the genetic networks of ALMS1 may lead to a better understanding of the role of ALMS1 in metabolic and neurosensory disease and may provide novel targets for therapeutic intervention.
Objectives: Angiotensin-converting-enzyme inhibitors (ACEIs) are among the most commonly used drugs in the management of cardiovascular disease. It is used as an antihypertensive and for the alleviation of progressive vascular injury. However, intake of ACEIs may lead to an adverse side effect, uncomfortable dry cough that occur in about 20-25% of patients. Although several genomic variants have been found to be associated with ACEI-induced coughing, there are no published data to adequately address pharmacogenetic utility among Filipino patients. This was undertaken to determine the prevalence and clinical association of candidate genomic variants among Filipinos. Methods: A case-control study involving 186 unrelated patients who were taking ACEI for at least 6 months was done (101 males, 85 females; 62 cases, 124 controls). DNA from blood samples were extracted and were genotyped using customized Illumina Goldengate microarray chips for 384 gene variants. Results: Results show that allelic variants of the genes ZPR1, ADAMTS7, CTB-129P6.7 and LOC157273 are significantly associated with ACEIinduced coughing (OR: 2.34, 3.120, 2.49 and 2.64, respectively, p<0.01).
Using genotypic modeling, ZPR1 shows a dominant trend, while ADAMTS7 and CTB-129P6.7 manifest genotypic patterns (Cochran-Armitage test, p<0.01). Further, an intergenic loci in chromosome 4 is also significant. Interestingly, using logistic regression, in addition to ZPR1, ADAMTS7 and CTB-129P6.7, eight variants located proximal to each other in the X chromosome have been associated with the ACEIinduced coughing. Conclusion: The study presents possible pharmacogenetic markers for Filipinos, as well as genomic regions of interest that may further shed light on the mechanisms of ACEI-induced coughing.

Competing interests
None declared.

P32
The use of "humanized" mouse models to validate disease association of a de novo GARS variant and to test a novel gene therapy strategy for Charcot-Marie-Tooth disease type 2D Thirteen GARS variants have been previously linked to CMT2D. Recently, diagnostic whole exome sequencing revealed heterozygosity for a novel, de novo, 12 base-pair deletion in exon 8 of GARS (c.894_904del12) in a one year-old female showing symptoms including hypotonia and weakness. This variant causes an in-frame deletion of four amino acids (E299-302Qdel, referred to as "ΔETAQ") within the catalytic domain of the enzyme and is thus likely deleterious. To validate ΔETAQ as the causative mutation, we are currently engineering a "humanized" mouse model in which both the normally functioning human sequence of exon 8 and the mutant ΔETAQ variant sequence of exon 8 have been introduced into the mouse genome. Methods: We have successfully engineered a mouse that expresses the wild-type human sequence of GARS exon 8 using CRISPR/Cas genome editing technology and are currently engineering a mouse that will express the mutant sequence. Once both strains are verified we will cross them to produce a compound heterozygote with the same putatively pathogenic DNA sequences as the patient (Gars ΔETAQ/+ ). Once established as stocks, the Gars ΔETAQ/+ mice will be evaluated for features of neuropathy observed in other established mouse models of GARS-linked CMT2D. The Gars ΔETAQ mice will also provide a humanized disease model for preclinical studies. Previous studies predict that knockdown of mutant GARS should be therapeutically beneficial for patients with CMT2D, provided wild type GARS is preserved. Therefore, we developed a gene therapy strategy that involves the allele-specific knockdown of mutant GARS transcripts by virally delivered RNAi. RNAi vectors designed to target the ΔETAQ variant as well as other confirmed CMT2D-linked GARS variants have been developed and tested in vitro for knockdown efficacy and specificity. Results: The results of our in vitro studies confirm that we have developed several RNAi sequences that specifically target several GARS variants but not wild type GARS. Conclusion: Success with this novel gene therapy approach will provide a promising avenue for treatment of CMT2D and other dominantly inherited neuromuscular diseases. Objectives: Next generation sequencing (NGS) can be used to identify clinically relevant variants for accurate diagnosis, prognostic risk stratification, and identification of therapeutic targets for genotypematched trials in cancer. Our objective was to design methods for efficient prioritization of variants for interpretation and reporting. We describe a triaging algorithm to identify clinically relevant variants from tumour-only analysis of NGS in hematological malignancies. Methods: Blood or bone marrow DNA from 260 patients recruited in the Princess Margaret Cancer Centre's Advanced Genomics in Leukemia (AGILE) trial were profiled using the 54 gene TruSight Myeloid Sequencing Panel (Illumina). Variants were called using the Illumina MiSeq Reporter (MSR) software. Data were uploaded into a commercially available tool, Cartagenia Bench NGS, for filtering and analysis. Results: Of all variants detected by NGS (median 427, range 338-643 variants/case), 35% (median 150, range 125-172 variants/case) passed all MSR quality criteria. Applying a variant allele frequency threshold refined the data to 7.4% of the original dataset (median 30, range 16-48 variants/case). Reporting was restricted to wellcovered, exonic nonsynonymous, intronic splice site, and known pathogenic synonymous variants, resulting in a median of 4 variants/ case for manual review (range 0-13). When combined with our dataset of >600 interpretations across 8 hematological malignancies, this approach enabled rapid review and interpretation of previously known variants, and an effective system to prioritize novel variants in order of clinical actionability (Sukhai et al., 2015). We excluded variants with high germline population frequencies (median 50, range 42-62 variants/case) through the use of multiple reference population databases.
Conclusion: We describe our approach to prioritize NGS derived variants, based on data quality, functional effects, allele frequency, coverage depth, and coding effects. This approach iteratively utilizes our lab-developed variant knowledge base, and enables us organize and use variant interpretations to generate clinical reports. the tasks of collection, storage, transfer, sharing, and privacy protection. Currently, each analysis group must download all the relevant sequence data into a local file system before variation analysis is initiated. This heavy-weight transaction not only slows down the pace of the analysis, but also creates financial burdens for researchers due to the cost of hardware and time required to transfer the data over typical academic internet connections. Methods: To overcome such limitations and explore the feasibility of analyzing control-accessed sequencing data in cloud environment while maintaining data privacy and security, here we introduce a cloud-based analysis framework that facilitates variation analysis using direct access to the NCBI Sequence Read Archive through SRA Toolkit, which allows the users to programmatically access data housed within SRA with encryption and decryption capabilities and converts it from the SRA format to the desired format for data analysis. Results: A customized machine image (ngs-swift) with preconfigured tools, including SRA Toolkit and NGS Software Development Kit, and resources essential for variant analysis has been created for instantiating an EC2 instance or instance cluster on Amazon cloud. Performance of this framework has been evaluated using dbGaP study phs000710.v1.p1, and compared with that from traditional analysis pipeline, and security handling in cloud environment when dealing with control-accessed sequence data has been addressed. We demonstrate that with this framework, it is cost effective to make variant calls without first transferring the entire set of aligned sequence data into a local storage environment. Conclusion: This direct data access approach using NCBI SRA Toolkit from cloud for next generation sequencing analysis is more costeffective in terms of time and disc spaces being used for the analysis, and thus will accelerate variation discovery using control-accessed sequencing data.
Objectives: To identify genome-wide transcription start site activities in various mammalian cells, a worldwide collaborative project, FANTOM5 (Functional Annotation of Mammalian Cells 5) was organized. In this project, diverse range of mammalian samples (~2000 for human and~1200 for mouse, including primary cells, cancer cell lines, tissues, and transiting cells in time courses) was profiled to obtain promoter-level transcriptional atlas using high-throughput sequencers. To provide this large-scale data collection to the scientific community, we developed an integrated web resource, the FANTOM5 web resource. Methods: To support various sort of inspections and analyses, the web resource contains several tools. SSTAR (Semantic catalogue of Samples, Transcription initiation And Regulators) provides a wide range of analysis results as well as detailed information of individual samples; ZENBU, a data integration, data processing, and expression enhanced visualization system designed for big data genomics projects, provides interactive way to inspect the entire promoter activities measured in FANTOM5 interactively; and Table Extraction Tool (TET) provides an easy-to-use interface to download subsets of the overall FANTOM5 expression table in an efficient way. A BioMart instance and a track hub for UCSC genome browser enable us to access our TSS resources with widely used interfaces. Furthermore, PrESSto provides an interface to browse human enhancers identified in the FANTOM5 project, and Biolayout enable us to visualize biological states in a three dimensional expression space with interactive interface. Results: The web resource is accessible from the FANTOM5 portal page: http://fantom.gsc.riken.jp/5/.  Objectives: The frequency distribution of pharmacogenomics markers across the populations in the worldwide can differ in magnitude or be absent depending on the population being assessed. The CYP3A5*3 (rs776746) is the most frequent and well-studied variant allele of CYP3A5. This polymorphism have been related to the guidelines regarding the use of pharmacogenomic tests in dosing of immunosuppressive Tacrolimus drug published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium (CPIC). The CYP3A5*3 genotype is polymorphic in several continental and large populations, for example the minor allele frequency (MAF) of rs776746 marker in Europeans and Africans populations is opposite, while A allele is the minor (0.036) for Europeans G allele is the minor (0.15) in Africans. However, this pharmacogenomic marker is not well-studied in the admixed and Native American populations. The objective in this study is evaluate the distribution of allele frequencies for the CYP3A5*3 variant across the admixed and Native American (Mexican) populations. Methods: Genotypes for rs776746 from the Mexican Genome Diversity Project database were analyzed. Allele frequencies were calculated for 4 Native American-Mexican populations located in north, central and southwest Mexico territory plus 370 Mexican mestizos and 60 European, 60 African, 90 East Asian from the HapMap project.
The Fst statistic was analyzed as measure of the degree of genetic differentiation pairwise populations. Results: Extreme genetic differentiation among HapMap populations for was observed for CYP3A5*3 (rs776746) as one would expect, particularly for the comparisons of African and European ancestry populations. However, the largest Fst statistic and allele frequencies values was found among Native Americans. For example, the allele frequency of CYP3A5*3 allele is more than 6-fold higher in Tepehuanes (0.43) than Zapotecas (0.07) with Fst value of 0.1746 (largest divergence). Conclusion: We identified novel CASR variants that have a potential to be related to serum calcium levels in Korean population. Inter-ethnic differences were suggested in some associated SNPs. Given the significant role played by calcium in many diseases and cell signaling, further studies with more East Asian subjects or meta-analyses on them may enable validation of our results and identification of novel genetic loci associated with serum calcium levels. Objectives: African Americans experience disproportionately higher prevalence of type 2 diabetes and related risk factors. Little research has been done on the association of ADIPOQ gene on type 2 diabetes, plasma adiponectin, blood glucose, HOMA-IR and body mass index (BMI) in African Americans. The objective of our research was to assess such associations with selected SNPs. The study included a sample of 3,020 men and women from the Jackson Heart Study who had ADIPOQ genotyping information.
Methods: Unadjusted and adjusted regression models with covariates were used with type 2 diabetes and related phenotypes as the outcome stratified by sex. There was no association between selected ADIPOQ SNPs with type 2 diabetes, blood glucose, or BMI in men or women.
Results: There was a significant association between variant rs16861205 and lower adiponectin in women with minor allele A in the fully adjusted model (β(SE) p = -.13(0.05), 0.003). There was also a significant association with variant rs7627128 and lower HOMA-IR among men with minor allele A in the fully adjusted model (β(SE) p = -0.74(0.20), 0.0002).
Conclusion: These findings represent new insights regarding the association of ADIPOQ gene and type 2 diabetes and related phenotypes in African American men and women.
Competing interests None declared. Objectives: Calcium is a universal intracellular messenger that has an important role in controlling various cellular processes. In this study, we attempts to evaluate the genetic polymorphisms that affect serum calcium levels in Korean population through a two-stage genome-wide association study with the sample of 8642 unrelated Koreans (4558 for discovery and 4093 for replication). Methods: Study subjects were selected from an ongoing populationbased study known as the Korean Genome and Epidemiology Study (KoGES) and genotyped using the Affymetrix Genome-Wide Human SNP Array 5.0. We applied standard quality control parameters such as SNP call rate >95%, minor allele frequency >5% and HWE P>0.001. After this quality control process, genotypes of 4558 individuals for 1219546 autosomal SNPs were used for stage 1 association analysis. Results: Using SNP arrays, we discovered 963 associated SNPs in stage 1, and replicated 105 SNPs among them in stage 2. We examined them in a combined set of stage 1 and 2 samples and observed that 65 SNPs were significantly associated with serum calcium levels. Among them, rs13068893 in the CASR gene showed the strongest significance (P=3.85×10−8). Considering the high allele frequency and significance level of the rs13068893 C>G in the CASR gene, this SNP may have a key role in regulating the serum calcium level. We also successfully replicated the four loci (CASR, CSTA, DGKD and GCKR) using our data set that have been previously reported to be significantly associated with calcium levels in Europeans and Indians. Conclusion: In this exome sequencing study, we identified a novel low frequency loci. We demonstrate an alternative splicing mechanism by which the GFI1B rs150813342 variant suppresses formation of a GFI1B isoform that preferentially promotes megakaryocyte differentiation and platelet production.
autosomal recessive condition may serve as carriers, each harboring one copy of the mutated gene without showing signs and symptoms of MAP. The MUTYH protein interacts with six partners, but only four of these proteins showed direct physical interactions in our study. These proteins were hMSH6, hPCNA, hRPA1, and hAPEX1. We also for the first time examined specific interactions of these protein partners with MAP associated MUTYH mutants using molecular dynamics simulations. These approaches provided tools for exploration of the conformational energy landscape accessible to these protein partners. The study also determined the impact before and after energy minimization of protein-protein interaction (PPI) and binding affinities of MUTYH wild type and mutant forms, including interactions with other proteins. Taken together, this study has provided innovative insights into the role of MUTYH and its interacting proteins in MAP.
Conclusion: This study provides interesting information and will open up a fresh avenue for the FAP researchers. We also strongly believe that the identified important features of the HMUTYH mutations through our In-silico study will support further In vitro studies in future.